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SUMMARY 
 Osteoarthritis (OA) is the most common disease of the knee. OA is characterized 
by damage to the articular cartilage, underlying bone, and chronic inflammation of the 
joint tissues, leading to the progressive loss of joint function, increased disability, and 
reduced quality of life. In OA, the role of chronic low-grade inflammation has been 
implicated in disease progression. In wound healing, lymphangiogenesis, or the 
formation of new lymphatic vessels, is central to inflammation resolution. However, in 
the osteoarthritic synovium, lymphatic vessel density is decreased in later stages of OA, 
and changes in the microcirculatory environment may be responsible for joint 
dysfunction. Blood vessels and lymphatic vessels (the microvasculature) play a critical 
role in tissue maintenance and may impact OA development and treatment strategies. 
Therefore, our main objective was to understand joint clearance mechanisms under 
normal and diseased conditions. This thesis's long-term goal was to establish 
biomolecular engineering strategies to assess microvascular function in normal and OA 
joints and assess ex vivo lymphatic function using lymphatic tissue culture devices. 
 In Aim 1, we used near-infrared (NIR) imaging techniques to non-invasively 
evaluate venous and lymphatic drainage in the naïve knee joint in vivo. We then 
perturbed joint homeostasis using exercise or endothelin-1(ET-1), a cytokine elevated in 
human OA with strong vascular tonic activity and investigated the effects on 
microvascular function and clearance mechanisms. In Aim 2, we used these techniques to 
determine how microvascular clearance changes during OA progression in a post-
traumatic OA model in the rat. Finally, in Aim 3, we used two ex vivo systems to study 
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two aspects of lymphatic physiology. In the first application, we used a lymphatic 
pressurization device to study the effect of post-traumatic and simulated OA 
microenvironment on femoral lymphatic contractility. In the second application, we used 
an ex vivo polyethylene glycol (PEG) hydrogel culture platform to investigate mature 
collecting vessel collateralization 1) in a simulated OA environment and 2) in an 
inducible knockout of epsins 1, 2, which regulate receptor internalization in 
lymphangiogenesis.  
Collectively, we found that exercise or ET-1 can alter joint clearance and that OA 
induction in the rat has differential effects on venous and lymphatic clearance. 
Additionally, we found that treatment with human OA synovial fluid reduces lymphatic 
collecting vessel function and collecting vessel growth ex vivo and that epsin deletion 
decreases lymphatic collecting vessel sprouting. Thus, these studies increased the 
fundamental knowledge about the role of the microvasculature, specifically lymphatics, 
in normal and diseased joint function and provided some ex vivo context on how 




CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Osteoarthritis (OA) is the most common disease of the joints. It is characterized by 
damage to the articular cartilage, underlying bone, and chronic inflammation of the joint 
tissues, leading to the progressive loss of joint function, increased disability, and reduced 
quality of life1,2. OA's current standard of treatment is rehabilitation and exercise to 
maintain joint mobility, palliative treatment to manage pain, or in severe cases, joint 
replacement surgery for late-stage disease3. In OA, the role of chronic low-grade 
inflammation has been implicated disease progression. In wound healing, 
lymphangiogenesis, the formation of new lymphatic vessels, is central to inflammation 
resolution4,5. However, in the osteoarthritic synovium, lymphatic vessel density 
decreases, which may be involved in the observed reduction in fluid and macromolecule 
clearance from the joint and sustained inflammation6. Thus, blood vessels and lymphatics 
play a critical role in joint maintenance and could potentially affect OA development, 
progression, therapies, and rehabilitation7–9; therefore, it is necessary to understand 
clearance mechanisms under normal and diseased conditions. 
The long-term goal of this work is to establish bioengineering strategies to assess 
and modulate microvascular function in the context of OA. The objective of this thesis 
was to determine the role of microvascular function in OA progression. The central 
hypothesis was that microvascular (lymphatic and venous) clearance, central to the 




techniques to measure tracer clearance in rat knee joints using near-infrared imaging 
(NIR), quantitatively assessed microvascular clearance in a clinically relevant rat model 
of OA, studied lymphatic contractility ex vivo, and utilized a polymer-based biomaterial 
scaffold to study lymphangiogenesis ex vivo. Using these techniques, we furthered our 
understanding of the potential role of microvascular function in osteoarthritis 
progression. 
Specific Aims 
1.1.1 Specific Aim 1: Quantify microvascular clearance in naïve rat joints 
The primary objective of this aim was to assess microvascular clearance in the 
joint. Size is a significant determinant of how materials clear interstitial spaces in vivo; 
therefore, we validated that we could engineer NIR tracers to target venous uptake with a 
small 1-2 kDa NIR dye and lymphatic uptake with a 40 kDa polyethylene glycol (PEG) 
conjugated NIR dye and utilized the size-dependent nature of venous and lymphatic 
uptake. We then utilized this approach to assess the effects of endothelin 1 (ET-1), a 
vasoactive compound chronically elevated in OA, on joint clearance. Lastly, we further 
assessed the role of exercise in joint clearance. We hypothesized that ET-1 would 
significantly reduce lymphatic clearance. Additionally, we hypothesized that venous and 
lymphatic clearance would increase with exercise. 




A growing body of literature has implicated lymphatic dysfunction in OA6,10–14 
and the positive effect of exercise on patient outcomes15–18. However, no groups have 
directly investigated: 1) venous and lymphatic drainage simultaneously in a clinically 
relevant model of OA, 2) the effect of exercise on venous and lymphatic drainage during 
OA progression. Given this, we investigated the effect of OA on microvascular function 
via clearance. OA was induced via a post-traumatic rat model of OA, the medial 
meniscus transection (MMT) surgery, and in vivo microvascular clearance was assessed. 
After we assessed joint clearance longitudinally as a function of surgery, we evaluated 
the effect of exercise on clearance during MMT surgery. We quantified the clearance of 
tracers. Our working hypotheses were that microvascular mediated clearance would 
decrease over time in the MMT and that exercise would increase the clearance of tracers 
from the joint space in OA. 
1.1.3 Specific Aim 3: Using ex vivo platforms to assess lymphatic contractility and 
lymphangiogenesis 
Ex vivo platforms have previously allowed groups to study the factors that affect 
lymphatic collecting vessel contractility and lymphatic collecting vessel segment 
growth19–24. In this aim, we used these two platforms to study lymphatic collecting vessel 
function and lymphangiogenesis in the context of OA. We used a custom ex vivo 
functional testing setup to assess rat femoral lymphatic collecting vessel contractility 
after MMT surgery or after perfusion with human OA synovial fluid (OASF). 
Additionally, we used a PEG hydrogel platform to study OA synovial fluid's effect on 




used the PEG hydrogel platform to understand how endothelial epsins regulate 
lymphangiogenesis using mouse flank collecting vessel segments. Our working 
hypotheses were that lymphatic vessel pumping function would decrease in MMT 
isolated vessels and OASF treated vessels and that OASF would reduce lymphatic 
collecting vessel growth. Additionally, we hypothesized that OA synovial fluid would 
decrease lymphangiogenesis, while epsin deletion would increase collecting vessel 
lymphangiogenesis. 
1.2 Significance and innovation 
1.2.1 Biomaterials-based diagnostic approach to determining joint health 
Classically lymphoscintigraphy (the identification and imaging of lymphatics via 
tracers) has been executed via radiolabeled dyes used in the joint to observe albumin or 
dextran clearance. ICG is currently used clinically for sentinel node biopsy procedures in 
vivo. However, given its propensity to non-specifically bind to proteins, indocyanine 
green (ICG) effects on lymphatic function are unknown. In this thesis, we showed that 
PEG NIR tracers, which do not exert long-term effects on lymphatic contractility25, can 
be used to assess venous and lymphatic clearance from joint space simultaneously. This 
work is innovative because it couples NIR imaging with the simultaneous assessment of 
venous and lymphatic drainage in various joint health states and interventions. 




The MMT model and other relevant pre-clinical models have uncovered various 
aspects of OA's pathogenesis and investigated the efficacy of therapeutics on OA 
progression26,27. However, the effects of OA on lymphatic collecting vessel function and 
the contribution of lymphatic collecting vessels to joint health. We know there may be 
proliferative changes or loss of lymphatics in OA. To isolate the effect of altered 
lymphatic function on OA, we assessed how a lymphatic collecting vessel treatment 
affects contractility. This work is novel because no one has isolated lymphatics from 
arthritic animals and tested their capacity to pump. Additionally, no groups have assessed 
the effects of human synovial fluid on lymphatic contractility ex vivo. 
1.2.3 PEG-based platform to study collecting vessel lymphangiogenesis 
Maleimide terminated multi-arm PEG hydrogels can help elucidate the effects of 
materials stiffness and soluble factors on angiogenesis in vitro28,29. Here used this 
platform to study the effects of synovial fluid extracted from human OA patients on 
lymphangiogenesis and to study how epsins regulate collecting vessel 
lymphangiogenesis. This work is different from other approaches because it seeks to 
understand how synovial fluid from OA patients affects mature collecting vessel 
lymphangiogenesis and remodeling. Additionally, this work is different from most 
lymphangiogenesis studies as most of them are performed using LECs or in vivo at initial 
lymphatic beds using the mouse ear or zebrafish30–36. Furthermore, mature collecting 






Overall, this thesis sought to further our understanding of clearance mechanisms 
of healthy and diseased joints. Aim 1 established NIR imaging's utility and sensitivity to 
capture the clearance of sized tracers from the joint space and determined that exogenous 
vasoactive factors could decrease outflow from the joint.  In Aim 2, we used our pre-
clinical OA model to quantify the dynamic longitudinal changes in venous and lymphatic 
uptake with the techniques established in Aim 1. In Aim 3, we used ex vivo tissue 
mechanical testing to investigate how OA affects tissue and ex vivo tissue culture to 
assess the effect of epsin deletion and a simulated OA environment on collecting 
lymphatic vessel lymphangiogenesis. This body of work can serve as multiple platforms 
capable of investigating detectable changes in clearance in human OA and screening 






CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 
2.1 Osteoarthritis Epidemiology and Impact 
Osteoarthritis (OA) is the most common form of arthritis affecting millions of 
people worldwide, with notably more than 3 million additional cases diagnosed per year 
in the US 40–42. While OA can affect all joints, the hands, knees, hips, feet, and spine are 
the most commonly affected areas43. OA symptoms include pain, joint dysfunction, and 
deformity, while gender, age, obesity, and biomechanical predisposing factors seem to 
affect the development of OA41,44–47. OA is characterized by the gradual degradation of 
the articular cartilage, along with changes in the subchondral bone, synovium, meniscus, 
tendons, and muscles48–51. The current understanding of the pathophysiology of OA is 
evolving from what was initially thought to be only a mechanical disease caused by 
cartilage degradation progressed to a multi-factorial process mediated by the 
immunological response and abnormal mechanics47,51. 
OA was historically associated with increasing age as OA's manifestations were 
primarily reported in older populations52,53. As life expectancy increases, the number of 
people affected with OA will likely increase with time. Additionally, a recent systematic 
review of OA prevalence within tactical athletes (e.g., the military, firefighters, law 
enforcement, first responders) revealed that OA incidence was significantly higher in 
these exposed athletes when compared to non-exposed controls, which was likely due to 
increased and repetitive bending, squatting, lifting, and kneeling associated with these 




dysfunction, and identifying population-specific risk factors will allow for the 
development and implementation of strategies that reduce OA incidence.  
OA has devastating effects on physical and mental health2,55,56 as well as social 
support and social function1. This disease reduces the quality of life of hundreds of 
millions globally and substantially burdens the global healthcare system. Behind 
back/neck pain, osteoarthritis is the leading cause of musculoskeletal disability globally57. 
In terms of joints affected by OA, knee OA accounts for a large percentage of OA 
diagnoses precisely because of the knee's load-bearing nature and its association with 
obesity58. Those with knee injuries of particular interest to the OA community carry a 
high risk for post-traumatic OA (PTOA) development. For example, those with an ACL 
injury are 13% likely to develop PTOA59, while those with a combined ACL meniscal 
injury are 21-48% likely to develop PTOA 10 years post-injury60. Destabilization of the 
joints leads to aberrant mechanical loading, propagating tissue damage, leading to 
PTOA61.  
2.2 Joint Anatomy and Physiology 
The synovial joint, like the knee, is a specialized collection of tissues that enables 
joint movement and is a critical part of the musculoskeletal system62. Joints are named 
and aptly characterized by the movement they allow. For example, synovial (diarthrodial) 
joints differ from fibrous (amphiarthrodial) and rigid (synarthrodial) due to the synovial 




the tendons and ligaments, which work in conjunction with the skeletal muscle and 
cartilage to move the large bones. 
2.2.1 Articular Cartilage 
Articular cartilage (Figure 1) is a specialized tissue where the extracellular matrix 
(ECM) is mainly composed of type II collagen and aggrecan (a proteoglycan that binds 
glycosaminoglycans (GAGs))63. GAGs possess carboxyl and sulfate groups that confer a 
net negative charge to the ECM; due to this negative charge, articular cartilage imbibes 




water and is well hydrated64,65. Distinct layers characterize the tibia and femur's articular 
cartilage: the superficial zone, intermediate zone, deep zone, and transitional zones, 
including tidemark and calcified cartilage63. These different zones provide structural 
support during physiological loading of the cartilage during movement or while 
stationary. The superficial zone is responsible for providing structural support to the 
shear loading of articular cartilage and exchanges with the synovial fluid (SF). The 
intermediate zone is a transitional zone and can resist shear and compressive shear 
forces66. Cartilage's deep zone is responsible for supporting compressive loads66. The 
tidemark and calcified cartilage are structurally more like bone and connect the cartilage 
to the tibia and femur. Chondrocytes within the intermediate and deep zones are 
responsible for ECM synthesis and maintenance of the tissue67. The meniscus is a 
fibrocartilaginous structure between the medial and lateral bone surfaces and allows 
shock absorption68. External forces generated from daily activities result in a complex 
combination of shear, tensile and compressive stresses in cartilage. The unique 
composition and structure of collagen within the different cartilage zones allow for the 
tissue's adequate response to external forces. Like most tissues, cartilage is viscoelastic, 
and its behavior is strain rate dependent69. For viscoelastic materials, the application of 
stress causes temporary deformation if the stress is quickly removed, like elastic 
materials, but permanent deformation if it is maintained, like a fluid70. The articular 
cartilage is avascular and exchanges nutrients via the vascularized subchondral bone and 
synovial fluid71. 




Multiple ligaments have insertion sites within the joint and outside the joint to 
stabilize the joint (Figure 2). Some of the main ligaments include the anterior cruciate 
ligament (ACL) and posterior cruciate ligament (PCL), preventing posterior-anterior 
displacement of the joint. The transverse ligament (not pictured) connects the two lateral 
and medial meniscal surfaces.  Outside of the joint capsule, the patellar ligament/tendon 
connects the patella to the tibia and femur and primarily functions as a pully for the 
quadricep. Lastly, the medial collateral and lateral collateral ligaments (MCL & LCL) 
prevent the knee joint from bending in the medial and lateral directions. Most of the joint 
tissues like the cartilage surfaces, tendons, and ligaments have limited regenerative 
capacity, attributed to lack of vascular supply and inadequate repair mechanisms72. 




Therefore, all these tissues work in conjunction to reduce the likelihood of joint 
hyperflexion or tendon and ligament tears73. 
2.2.3 Synovial Membrane 
The synovial membrane is another specialized tissue that serves many functions 
with the joint: 1) synoviocytes line the membrane and are in contact with the synovial 
fluid to synthesize hyaluronic acid (HA) and lubricin and keep critical components from 
leaving the joint space 2) the synovial membrane house the vasculature that participates 
in fluid exchange, namely the lymphatic and blood capillaries, and 3) the synovial 
membrane houses resident immune cells and participates in immune surveillance74–77. 
The synovial membrane and joint capsule make up connective tissues that form a sleeve 
around the synovial membrane's lateral aspects78. The synovial lining's intimal surface 
contains two synoviocytes, type A synoviocytes from macrophage lineage and type B 
synoviocytes, derived from fibroblasts74,79. The intimal layer of the synovium is generally 
1-2 cells in thickness, while the subintimal layer contains scattered blood vessels, 
lymphatic vessels, lymphocytes, and macrophages80. The vascularized subintimal layers 
allow for fluid and molecule balance and mediating immune cell surveillance. 
Synoviocytes synthesize and secrete HA in a mechanosensitive manner81. Increased 
synoviocyte loading through joint motion leads to increased HA production and secretion 
into the synovial fluid matrix. Proteoglycan 4 (PRG4 or lubricin) is synthesized by 
superficial chondrocytes and synoviocytes82–84. The mechanical regulators of lubricin 
synthesis are not as well-known as HA; however, chondrocytes exposed to an injury can 




2.2.4 Synovial Fluid 
Synovial fluid is a viscous lubricative fluid within the joint space integral to the 
function of cartilage and the transport of solutes to different joint tissues86. The primary 
function of synovial fluid is to lubricate the joint surfaces and reduce friction between 
articular cartilage77. Due to the limited capacity for cartilage to repair, maintenance of the 
synovial fluid composition is essential72. Synovial fluid contains lubricin, HA, surface-
active phospholipids (SAPLs), and albumin, all of which work to lubricate the joint 
surfaces, maintain oncotic pressure, and serve as a medium for nutrients, waste, and 
cytokines to traffic through. Lubricin, a 0.25 MDa glycoprotein that is a critical 
component of the joint lubrication process, was believed to participate directly in 
boundary lubrication87,88. However, later it was discovered that the primary function of 
lubricin was to transport SAPLs to the cartilage surface, and these SAPLs account for 
roughly 10% of the weight of lubricin and directly lubricate the cartilage surfaces89–91. 
Albumin is a 66 kDa protein that serves as a ubiquitous carrier molecule in the 
bloodstream, and interstitium also helps increase synovial interstitial fluid viscosity and 
exerts interstitial oncotic pressure92. Albumin also binds lipids, anions, peptides and thus 
can help drive the lubricative role of SAPLs by helping to carry them into the joint space 
from the synovium92,93. 
A net imbalance in the Starling forces drives the ultrafiltration of plasma into the 
joint space9,94. Oncotic pressure drives fluid flow and materials within that fluid out of 
capillary fenestrations and into the joint space8. The net negative charge of the synovial 




fluid is to help maintain hydrostatic pressure within the joints. Without SF, joint loading 
would force water to escape due to a large favorable hydrostatic pressure gradient 
rapidly95. However, due to the electrostatic interactions and considerable osmotic 
pressure generated by SF, this is averted. The reflection of the large SF constituents by 
the synovial membrane is a vital contribution to joint maintenance96. Additionally, HA 
polymer entanglements result in significant HA and water retention in the joint, leading 
to consistent and adequate lubrication of the cartilage surfaces97. 
2.3 Joint Fluid Transport 
Interstitial volume and protein concentrations are maintained in tissues via 
microvascular filtration, lymphatic return, and interstitial storage98. Due to the favoring of 
capillary filtration (movement from the blood vessels into the tissues), fluid would 
accumulate in the tissues resulting in pathologies like lymphedema without the 
appropriate vascular machinery99. Each tissue within the joint has its intrinsic sieving 
capacity/pore size/hydraulic conductance, which dictates which molecules can be present 
within the tissue and how quickly they move through them100,101. Additionally, our lack 
of understanding of how things can enter and exit tissue spaces in health and disease 
complicates our ability to understand disease mechanisms and appropriate treatment 
strategies. 
2.3.1 Cartilage, synovial fluid, and synovial membrane transport 
Due to its avascularity and small pore size (6 nm), cartilage relies on diffusion to 




growth factors during joint motion, with larger molecules affected more by cyclical 
mechanical loading than small ones103,104. Load-induced interstitial fluid pressure changes 
and diffusion transports molecules within the matrix. These loads can are induced by 
sliding (shear) or compression on the cartilage surfaces105,106. The synovial fluid, like the 
cartilage, is an extracellular compartment that serves as a medium for the movement of 
nutrients and growth factors. The pore size of synovial fluid has not been studied 
extensively; however, solutions crosslinked HA solutions at physiological concentrations 
have pore sizes between 30 to 500 μm107. Like cartilage, small solute movement through 
the synovial fluid via diffusion is dominant86. Synovial fluid is in constant exchange with 
the surrounding synovial membrane and cartilage. 
The synovial membrane is the first or final extracellular space that a solute entering 
or leaving the joint must traverse. The synovial membrane's intimal and subintimal layer 
contains an interstitial matrix composed of collagens, GAGs, proteoglycans, fibronectin, 
and laminin75. Interstitial matrix proteins significantly affect the synovium's permeability, 
as demonstrated by increased hydraulic conductance of the synovium in the presence of 
collagen sparing protease108. The pore size of the synovial membrane is approximated to 
be between 20–90 nm109,110. Once in the synovial matrix, there are two vascular routes by 
which materials can clear. Radiolabeled iodine and albumin drainage from the joint has 
demonstrated the size-based clearance of tracers, as iodine and albumin cleared through 
circulatory and lymphatic uptake, respectively111. Small molecules (< 5 nm)are cleared 




molecules112. Large molecules ( > 10 nm) cannot leave through venous circulation in 
most tissue beds and are cleared mostly via lymphatic circulation113–115. 
2.3.2 Effect of intra-articular pressure and hydraulic conductance on joint transport 
Intra-articular pressure (IAP) is dictated by various factors in the healthy joint, 
including joint position, synovial fluid composition, and activity levels. With the 
increased extension of the leg, the joint pressure decreases in humans, demonstrating that 
joint angle changes hydrostatic pressure within the joint. IAP is negative when not in 
motion and becomes momentarily positive with active joint motion116. Additionally, 
increases in IAP increase the hydraulic conductance of the synovium, likely mediated by 
increased extracellular gaps117. 
Colloid osmotic pressure has a more negligible contribution from HA than from 
albumin in the joint; however, hydraulic conductance is affected by HA 
concentration118,119. The viscosity of HA concentrations below 1.35 mg/mL behaves 
linearly, however above 1.35 mg/mL, the effects of HA chain interactions increase the 
linear rate at which viscosity increases with concentration and serves as a mechanism to 
improve HA retention118. As HA chain length decreases, its ability to buffer flow 
significantly decreases119. Experimentally, the reflection of HA is size-dependent as the 
synovium entirely reflects 2 MDa HA while smaller HA chains are cleared increasingly 
as their size decreases109,110. 
 While exercise is an essential determinant of human health, exercise's effect on 




and menicsus120. Increases in IAP via injection experimentally have shown increased 
downstream femoral lymphatic flow by 16%, showing that downstream lymphatic 
function could be increased by modulating IAP121. However, little is known about the 
contribution of exercise to flow from the joint. To date, few have shown the effect of 
exercise on synovial fluid transport84,120,122–124. These studies have assessed the effect of 
joint motion or exercise on material distribution or biomolecule synthesis but not 
downstream transport. Exercise has been shown in other tissues to increase blood and 
lymphatic flow to and from the tissue125–127. However, given the unique chemical 
composition of the synovial fluid and synovial membrane, the effect of exercise on joint 
clearance is a significant knowledge gap that must be addressed to further our 
understanding of how synovial joints function, given that exercise is a critical component 
of overall human health. 
2.4 Circulatory System Anatomy and Physiology 
In mammals, the circulatory system involves two interconnected systems that 
manage the transport of fluids through the body. The cardiovascular and lymphatic 
systems and their functions are reviewed in great detail by Miller et al.128. The 
cardiovascular system provides nutrients to tissues in the body via the blood and uses this 
same highway to transport waste materials away from the tissues128. Once materials reach 
the tissues, the lymphatic system is responsible for three main functions: 1) remaining 
interstitial fluid transport, 2) immune cell trafficking, and 3) intestinal lipid absorption 
and overall lipid homeostasis129. In addition to the circulatory system's essential nutrient 




long-range communication of tissues through cytokine/hormone signaling and immune 
cell surveillance by providing conduits by which these interactions occur130,131. 
The cardiovascular system is composed of hierarchical vessel networks with a 
centralized pump, the heart. The largest is the artery (0.1-20 mm in diameter) which 
transports blood out of the heart into smaller arterioles (< 100 µm in diameter)128. 
Arterioles propagate the blood into smaller capillaries (5 to 10 µm in diameter) where 
nutrient and fluid exchange occurs at the tissues128. The venules (10-100 µm) transport 
the deoxygenated blood away from the tissue and return it to the heart via the veins, 
which have valves (millimeters in diameter)128. At rest, the mean velocity of blood flow 
in the larger blood vessels is approximately 10 cm/sec132, while in the capillaries, the 
average blood velocity is roughly 1/10th of that in the larger vessels133. The intimal layer 
of large and medium-sized blood vessels contains blood endothelial cells (BECs). The 
medial layer contains support cells and ECM that support the vessel's contractility 
functions and provide structural rigidity. Finally, arterioles contain smooth muscle cells 
which contract to tightly regulate blood pressure and blood flow to the appropriate 
tissues128. The mechanisms that regulate vascular tone in blood vessels have been 
reviewed in great detail by Sandoo et al.134. 
The lymphatic system is the other circulatory system and originates from the 
tissues at the capillary level, aptly named initial lymphatics135. Initial lymphatics (10-60 
µm in diameter) collect lymph from the interstitial spaces to more mature pre-collecting 
vessels, which are intermittently lined with smooth muscle cells, larger than lymphatic 




vessels (1-2 mm in diameter), which have complete smooth muscle cell coverage and 
valves that help transport lymph against an adverse pressure gradient back to the systemic 
circulation via lymph node venous exchange and emptying the thoracic duct into the left 
subclavian vein129,137. Thus, collecting vessels transport lymph through lymph nodes 
which serves two main functions: 1)lymph nodes return 4L of the 8L of interstitial fluid 
that remains from capillary filtration back to the venous circulation138 2)lymph nodes are 
where antigen-presenting cells and naïve lymphocytes communicate and initiate immune 
responses139.  
The lymphangion is the segmental unit that encompasses the space between two 
valves in a mature collecting lymphatic vessel22,140. The pumping activity of lymphatics 
requires valves and specialized lymphatic smooth muscle-lined collecting vessels that, 
contrary to vascular smooth muscle cells, exhibit strong intrinsic phasic contractions to 
drive lymph downstream23. Lymphatic pumping is controlled by a variety of intrinsic and 
extrinsic factors. Lymphatic vessels have their intrinsic pacemaking activity controlled by 
the smooth muscle cells141. Fluid shear and transmural pressure can modulate this 
intrinsic pacemaking activity. Ex vivo perfusion and pressurization systems have been 
used to control flow and transmural pressure across isolated lymphatic vessels21,142–147. 
Under conditions of low flow, as the lymphangion fills with lymph, transmural pressure 
increases. The strength and frequency of the following lymphatic contractions are 
dictated by the rate at which the lymphangion fills148. In the cases of high filling and high 
fluid shear stress, lymphatics become more like a conduit and decrease contractility, and 




mechanical stimuli can also drive increased fluid flow in lymphatics and veins. These 
vessels can be located in or near the skeletal muscle, and they are subjected to external 
forces when muscles contract and relax; therefore, skeletal or smooth muscle pumps can 
improve lymph flow149.  
2.4.1 Angiogenesis 
Angiogenesis is the process by which blood vessels grow from existing vessels150. 
Classically angiogenesis occurs in response to a lack of oxygenation in tissues151152. 
Sprouting capillary angiogenesis is part of the normal response to injury and changing 
tissue demands in vivo. A significant number of factors exist that promote angiogenesis. 
The most well-known factor is vascular endothelial growth factor A (VEGF-A or VEGF). 
VEGF works in conjunction with a variety of factors to stimulate capillary angiogenesis. 
VEGFR2, the receptor for which VEGF-A has the highest affinity, is expressed by blood 
vessels and lymphatic vessels. 
A stable blood vessel is characterized by an inner endothelial monolayer called the 
tunica intima, which contains blood endothelial cells (BECs)128. The following layer is 
the tunica media, which contains smooth muscle cells, pericytes, and basement 
membrane. The tunica adventitia consists of connective tissue and elastin. Angiogenesis 
is initiated when growth factors interact with the endothelial cell cells. Growth factor 
signaling results in cell mitosis, increased migration, and proteolysis, which increases the 
permeability of the vasculature153. After disrupting the subintimal vessel layers, the 




gradients. BECs extend out into the matrix, degrade the matrix, and form tubular 
networks through vacuolar and pinocytic events154. Some of the most potent pro-
angiogenic regulators have been reviewed in great detail151 and include VEGF-A, 
fibroblast growth factor (FGF), angiotensin 1 and 2 (ANG-1 and ANG-2), transforming 
growth factor-beta (TGF-β), tumor necrosis factor-alpha (TNF-α). To eventually turn off 
the cellular cues, direct angiogenesis, arrestin, canstatin, and high molecular weight 
kininogen initiate vessel stabilization and terminate angiogenesis151. 
2.4.2 Lymphangiogenesis 
Lymphangiogenesis is the process by which lymphatic vessels grow from existing 
vessels. A stable lymphatic collecting vessel is defined by a tunica intima consisting of 
lymphatic endothelial cells, a tunica media consisting of lymphatic muscle cells and 
elastic fibers, and a tunica adventitia consisting of collagen and elastin, which help 
connect the lymphatic vessels to the surrounding tissue128. During embryonic 
development, lymphatic vessels originate from the cardinal veins (the pre-natal venous 
system)93. VEGF-C signaling is the primary driver of lymphatic growth from budding 
and initiates lymphatic sprouting from embryonic veins155. Vascular endothelial cells bud 
off the cardinal vein and, through PROX-1 signaling, differentiate into lymphatic 
endothelial cells that form collecting vessels, and ultimately smaller lymphatic capillaries 
grow in the mesenchymal tissue156. Lymphatic valves are formed as lymphatic collecting 
and precollecting vessels mature157,158. LECs in the collecting vessels downregulate 
PROX1, VEGFR3, and LYVE-1, except for valve-forming cells, and FOXC2 is another 




vessels mature, LECs secrete reelin into the extracellular matrix, which helps drive the 
recruitment of smooth muscle cells (SMCs) to collecting lymphatic vessels160. 
Postnatally, in response to growth factors like VEGF-C, LECs destabilize lymphatic 
vessels, extend long filaments into the extraluminal space that sample the ECM, and 
these cellular processes lead to the tunneling of thin vacuolized lymphatic sprouts 
through the ECM. As these groups of LECs tunnel through the ECM, intracellular 
vacuoles coalesce and form an intraluminal space, leading to a capillary lumen formation, 
as demonstrated in BECs37.  
In response to injury or inflammatory stimuli, capillary lymphangiogenesis can be 
stimulated: this process occurs through many of the same factors that drive angiogenesis 
(reviewed in detail by Aebischer et al.4) and include VEGF-C/D, IGF-1, IGF-2, PDGF-
BB, HGF, ANG-1, ANG-2, and FGF-2161. VEGF-C and VEGFR3 are the main lymphatic 
growth factor and receptors studied, and VEGF-C is mainly produced by inflammatory 
cells postnatally. The most abundant source of VEGF-A and VEGF-C in vivo is 
macrophages4. VEGF-C increases lymphatic vessel size in vivo, while VEGF-A increases 
lymphatic vessel proliferation and migration162. VEGF-D, another variant in the VEGF 
family, is the most potent regulator of lymphangiogenesis and, in its most post-
translationally modified form, has a high affinity for VEGFR2 and VEGFR3163. 
After VEGF-A and VEGF-C interact with their receptors, endocytosis or 
internalization of the receptor helps to modulate the signaling process. Epsins are 
endocytic adaptor proteins that regulate the internalization of VEGF receptors. EGFR 




synaptic vesicles in the brain and crucial in the receptor internalization process164. Eps15 
interacting protein, better known as epsin, was discovered with precipitate proteins from 
that endocytic machinery165,166. Epsins bind to membranes with specific cargo and 
connect them with the endocytosis machinery, and Epsin 1 and 2 are present in all 
tissues167,168. In the context of two inflammatory diseases, epsin function has been shown 
to be dysregulated. Several genetic models of epsin mice have been created to understand 
the role of epsins in the embryonic patterning and development of blood and lymphatic 
vessels. Researchers discovered that epsin 1 and 2 deletion in vascular endothelial cells 
during gestation results in death and highly disorganized vascular networks169. When a 
LEC-specific variant of these double knockout mice was generated, the mice are viable 
but have a series of abnormalities, including enlarged lymphatics, delayed or defective 
lymphatic valve formation, abnormal VEGFR3, and PROX1 signaling157. LECs from 
LEC-iDKO are more responsive to VEGF-C as assessed by tube formation assay in vitro, 
and in vivo corneal lymphatic vessels are more responsive to VEGF-C treatment157. 
Postnatal epsin deletion in LEC-iDKO lymphatics vessels does not affect the size and 
shape of lymphatic collecting vessels.  
Epsins have also been investigated as potential therapeutic targets in a variety of 
diseases. For example, in diabetes, epsins are also upregulated, leading to increased 
VEGFR3 degradation through oxidative stress157. In addition, LEC-specific deletions of 
epsin 1 and 2 lead to improved VEGF-C mediated lymphangiogenesis and the recovery 
of normal lymphangiogenesis in vivo. Another disease where epsins are augmented is 




facilitating pro-inflammatory macrophage recruitment and downregulating low-density 
lipoprotein receptor-related protein 1, which has anti-sclerotic properties. Therefore the 
myeloid-specific deletion of epsins reduces plaque formation via the upregulation of 
LRP-1 and generally led to decreased pro-inflammatory cytokines and an increase in an 
anti-inflammatory phenotype. 
Unlike angiogenesis, the growth and remodeling of mature lymphatic vessels after 
an injury has not been well-studied. Models in mice have provided some context and 
information about how lymphatic remodeling occurs post-natally171. In response to 
lymphatic obstruction or ligation, lymphatic pre-collecting vessels and capillaries form to 
help bypass the injury site to restore flow, demonstrating the regenerative capacity for 
lymphatics172136. Additionally, collateralization, or the formation of initial and 
precollecting lymphatics to restore fluid flow, has also been shown in the context of 
lymphatic obstruction or insufficiency173. However, the effect of inflammation on the 
capacity for collateral vessels to form from mature lymphatic vessels is not well 
established. Given the established link between OA and inflammation, it is unknown to 
which extent OA affects this process. To study the effect of individual cytokines and 
growth factors on lymphangiogenesis from mature collecting vessels, Bruyere et al. used 
a lymphatic ring assay in a collagen gel38.  Building off this type of ring assay, we can 
investigate the direct role of clinical OA samples in collecting vessels in growth and 
remodeling. This thesis will report the use of  PEG hydrogel to investigate how a 
simulated OA environment affects mature vessel sprouting and collateralization. 




To study the complex pathophysiological events in OA, several animal models 
have been developed. The three categories of animal models include naturally occurring, 
mechanical insult, and surgical insult and reviewed in great detail174. Spontaneously 
occurring animal models have the advantage of simulating spontaneous age-related OA. 
Dunkin Hartley guinea pigs have been the most widely used naturally occurring OA due 
to their rapid maturity to adults, size, and how OA manifests in human OA175. 
Spontaneous models are advantageous in some cases because they mimic the progressive 
loss of joint function in humans and can be used for studying early therapeutic 
intervention176,177. Additionally, they are fewer confounding effects such as surgeon 
technique and institutional differences in animal care178.  
The progressive joint destruction following post-traumatic injury is demonstrated in 
vivo in various animal models and ex vivo with whole joint studies or cartilage 
explants179. Additionally, different targets include the meniscus, the cartilage, and the 
ligaments of the surgically induced insults. Some mouse models include the 
destabilization of the medial meniscus, partial medial meniscectomy, and media 
meniscectomy. PTOA models are advantageous because they mimic OA's risk factors, 
which is a previous injury. 
In this thesis, we used the medial meniscal transection (MMT) induced model of 
PTOA due to its ability to rapidly develop pathological OA joint damage. The MMT 
model proceeds with a skin incision, blunt dissection of the muscle above the joint, 
transection of the MCL, and complete transection of the medial meniscus. This model has 




analysis182, and pain assessment26. Histologically, this model has been evaluated from 3-
12 weeks, with the early timepoints being used to evaluate the ability to prevent OA onset 
and with the later timepoints evaluating the ability to attenuate OA progression or 
evaluate the secondary effects of OA development. In this thesis, we evaluate the MMT 
model characteristics that have not to be established, including the venous clearance, the 
effect of exercise on clearance, and longitudinal lymphatic drainage over nine weeks. 
2.6 Osteoarthritis Pathophysiology 
OA's current standard of treatment is rehabilitation to maintain mobility, palliative 
treatments to manage pain, and joint replacement surgery for end-stage disease183. Low-
grade chronic inflammation is a crucial driver of OA, and it is well-documented that OA 
tissue and synovial fluid have increased serum proteins, complement components, and 
pro-and anti-inflammatory cytokines, immune cells,18,184–191. OA was considered a 
disease of wear and tear in the past, and the potential immune effects were not of 
significant interest. However, given that rheumatoid arthritis is associated with 
inflammation. The following section will discuss some of the pathological changes in OA 
and the degree to which they may affect fluid balance. 
2.6.1 Pathological changes in cartilage in OA 
The abnormal loading of cartilage through traumatic injury, altered biomechanics, 
or repetitive loading results in the destruction of the cartilage architecture69. The loss of 
the articular cartilage structure integrity changes its lubricative and fluid retention 




fibrillation and roughening cartilage defects195,196. Aside from the biomechanical 
function, there are changes in the chemical interaction. Cartilage degradation is mediated 
by pro-inflammatory cytokines, aggrecanases, matrix metalloproteinases, and nitric 
oxide195,197. Pro-inflammatory cytokines including interleukin-1β (IL-1β) and tumor 
necrosis factor α (TNFα) have been shown to promote cartilage degradation by 
stimulating the production of matrix metalloproteinases (MMPs)198,199. Ultimately 
cartilage fluid flow is likely to increase during OA progression due to the loss of 
structural integrity and proteoglycans70,200. 
2.6.2 Synovitis in OA 
Within the synovium, the innate immune system is the first line of defense against 
foreign materials. In OA, tissue damage is a feedforward process that drives the 
activation of the innate immune response, the release of pro-inflammatory cytokines, and 
the recruitment of inflammatory cells, resulting in inflammation of the synovium 
(synovitis)51,71,191,201–204.  
Functionally synovitis is associated with palpable joint swelling, sudden increases in 
pain as well as morning stiffness13,205. In the clinic, MRI and ultrasound are the primary 
imaging modalities by which synovitis is assessed206–209. Pathologically, synovitis 
presents cell hypertrophy and hyperplasia, the infiltration of immune cells (T-cells, B-
cells, macrophages), and increased angiogenesis and lymphangiogenesis210. While the 




relationship between synovitis and lymphatic function in terms of initial lymphatic 
uptake and downstream lymphatic function is significantly understudied. 
2.6.3  Synovial Fluid Changes in OA 
Changes within the synovial fluid matrix may also be responsible for OA 
progression in humans. Human synovial fluid samples assessed as a function of age in 
non-OA patients demonstrated an inverse relationship with patient age and the 
concentration of HA211. The mean size of HA within the joint in rheumatic diseases is 
significantly decreased212. Additionally, compared to non-OA synovial fluid, the 
lubricating ability of HA was not significantly lower, but the mean size was much lower 
(p = 0.1)213. The superficial cartilage boundary roughness and decreased synovial fluid 
quality likely lead to the insufficient lubrication of the cartilage surface in OA213. 
Changes in HA integrity (concentration and size) may also change the rate at which 
materials flow through the synovial fluid matrix, affecting overall joint homeostasis; 
however, the flow of materials through osteoarthritic synovium has not been extensively 
studied, and this a gap in knowledge211,214–217. 
2.6.4 Clearance Changes in Osteoarthritis 
Given the role of clearance in the maintenance of joint fluid balance, joint clearance 
is of great interest to understand the physiology of the joint during disease and understand 
if lymphatics may be a therapeutic target in OA. The body of research investigating the 
effect of OA on microvascular anatomy and physiology is a small subset of OA research. 




OA patients205. When clearance in OA patients was compared to RA patients, the study 
showed that clearance of proteins ranging from 6 – 18 nm in hydrodynamic diameter and 
determined that the synovial permeance, clearance, and flux were lower in OA to RA 
patients218. However, this seminal study was limited due to the lack of adequate non-OA 
controls, and these differences could only speculatively be attributed to decreased 
clearance in OA or increased clearance in RA. These in vivo clinical studies implicate 
critical changes in microvascular clearance in humans, but studying this in a rigorous and 
highly controlled manner has been challenging clinically. Thus researchers have utilized 
pre-clinical models to investigate various aspects of OA progression more precisely. 
A variety of pre-clinical models have been used to study the effect of OA on 
lymphatic clearance previously. Albumin clearance from the knee joint was increased 12 
weeks post-OA induction in an ACL-induced joint injury in the canine219. In normal 
healthy tissues, albumin is cleared primarily by lymphatics220; therefore, increased 
albumin clearance could be mediated by increased lymphatic drainage or synovial or 
venous integrity changes, either of which would lead to increased flow. Additionally, this 
study was a small study with no histological evidence to explain the increased albumin 
clearance. More recently, rodents have been used as a model to investigate the effect of 
OA surgery on ICG clearance11,14. In the mouse meniscal/ligamentous injury (MLI) 
model, ICG clearance was slower than Sham at 6, 12, and 20 weeks post-surgery11,14. In 
other studies utilizing a rat knee joint model, dextran at two molecular weights, 10 kDa 
and 500 kDa were used to determine MMT surgery's effect on joint clearance. Three 




slower than their respective naïve joints221. Significantly synovial retention of the 
Dextran was noted in this study by MMT rats compared to naïve age-matched rats, 
suggesting that synovial permeability is decreased during OA development. While these 
studies provided critical insight into clearance rates, clearance and microvascular 
transport routes remain unknown. 
While most studies have focused on functional transport measurements in the joint, 
a few studies have begun to investigate structural lymphatic changes in the synovium 
during disease. Recently clinical human synovial samples have been assessed for the 
presence of lymphatic vessels. In osteoarthritic synovium, there is decreased lymphatic 
vessel size and vessel number compared to cadaveric non-OA controls6,11. Additionally, 
joint effusion (swelling) was associated with decreased lymphatic vessel density and 
lymphatic endothelial cell fractional area. These data together suggest that lymphatic 
clearance changes may be responsible for joint effusion in OA6.  
Recently clinical human synovial samples have been assessed for the presence of 
lymphatic vessels. In osteoarthritic synovium, there is decreased lymphatic vessel size 
and vessel number compared to cadaveric non-OA controls6,11. Additionally, joint 
effusion (swelling) was associated with decreased lymphatic vessel density and lymphatic 
endothelial cell fractional area, suggesting that lymphatic clearance changes may be 
responsible for joint effusion in OA6.  
2.7 Osteoarthritis Treatment 




OA's current standard of treatment is rehabilitation to maintain mobility, palliative 
treatment to manage pain, and joint replacement surgery for end-stage disease. Over 
600,000 hip replacement surgeries and 300,000 knee joint replacement surgeries result in 
over 200 billion dollars in health expenditures every year183,222,223. Given current 
heterogeneity in treatment, there is an unmet scientific need in disease pathogenesis and 
an unmet clinical need for disease-modifying therapies for OA. 
A study recently conducted by the department of human health and services 
researchers looked at the efficacy of various therapies, including cell-based therapies, 
oral supplements, viscosupplementation, transcutaneous electrical stimulation, strength 
and agility training, aerobic exercise, and weight-loss diets. Exercise and physical therapy 
have the potential to serve as a baseline practice for those with OA to improve and 
alleviate their symptoms and outcome. Strength training, in general, has been shown self-
reported measures of pain and physical function in over 50–75%224.  Except for weight 
loss, general exercise, and agility training, most treatments demonstrated short-term 
benefits on pain and function3. Exercise and increased movement may improve disease 
outcomes through the increased clearance of inflammatory cytokines122. Additionally, 
cyclical joint movement may improve disease outcomes through the increased secretion 
of HA, which helps make the synovial fluid more viscous to lubricate and prevent the 
outflow of synovial fluid84.  
The delivery of HA-like molecules to the joint space is of clinical significance225–
227. Viscosupplementation with exogenous HA has been a long-explored strategy in OA, 




longer recommended due to lack of efficacy228. HA clearance has been studied in various 
animal models, and the articular half-life was in the range of 12-24 hours229,230. The 
residence time for larger viscosupplements vary and is mediated mainly by size and 
chemical modifications100. The food and drug administration has approved a variety of 
products which include Hyalgan (1997), Euflexxa (2004), Synvisc-One (2009), and most 
recently, Durolane (2017)231. One of the main reasons why viscosupplementation as a 
singular strategy for OA treatment has failed may be ignoring the multiple underlying 
causes of the disease. These treatments, in most cases, require multiple injections of HA; 
however, increased HA catabolism is one of the hallmarks of OA232,233. 
Viscosupplementation continues to be explored via alternative approaches that improve 
lubrication and residence time within the joints234. Durolane has shown increased 
residence time in the joint compared to other HA-based injectable viscosupplements235–
237.  
Platelet-rich plasma (PRP), a concentrated blood product containing high 
concentrations of factors that drive angiogenesis and cell recruitment, has recently been 
investigated as a potential therapeutic option for people with OA, with the ultimate goal 
of creating repair tissue in the cartilage238. A meta-analysis conducted has shown that in 
comparison to saline or HA injections, PRP improves self-reported outcomes 12 months 
post-injection and provides additional relief for patients with significant joint 
degeneration225.  
Total hip and knee arthroplasty are the standard of care for patients with end-stage 




increase life quality. One of the burdens of total knee replacement or total hip 
replacements is the costs associated with them, the burden they add, and the associated 
costs of adverse effects such as revision surgeries239. However, in some cases, the QOL 
indicators matched those without OA, suggesting that these methods are effective. 
However, many factors control patient outcomes, including patient age, weight, lifestyle, 
and surgery wait times which all are involved in the likelihood that arthroplasty would be 
successful240–242. In addition, the residence time of intra-articularly delivered therapeutics 
modulates their bioavailability and likely their efficacy of the pain treatment. Given 
current heterogeneity in treatments, there is an unmet scientific need to understand the 
involvement of lymphatics and clearance mechanisms of endogenous and exogenous 
viscosupplements in disease pathogenesis and progression.  
2.7.2 Targeting Lymphatics for Joint Diseases 
The two most common joint diseases are rheumatoid arthritis and osteoarthritis—
RA and OA symptomatically present with pain, stiffness, and decreased range of motion. 
RA differs in etiology from OA because auto-immunity is the main precipitating event, 
rather than biomechanical drivers. OA tends to develop unilaterally or in one place, 
whereas RA tends to be symmetrical and present in multiple joints. Synovial 
inflammation is one of the hallmarks of RA. This immune overactivity in RA leads to 
flairs that can be predicted and controlled therapeutically. Unlike OA, RA has various 
disease-modifying antirheumatic drugs, ranging from biologics like anti-TNFα and non-




clinical and pre-clinical success in treating RA, modulating lymphatic function is of 
interest in OA. 
A variety of biologics and pharmaceuticals have been used to try to modulate 
lymphatic function in rheumatic diseases. In the context of an inflammatory model of RA 
in mice, Wang et al. showed that blocking VEGFR3 activity could reduce synovial 
lymphatic function14. Additionally, they showed that Bortezomib (BTZ), an anti-cancer 
medication used to treat multiple myeloma and mantle cell lymphoma, inhibits pro-
inflammatory cytokines in the T cells of RA patients, reduces inflammation in RA in rats, 
and suppresses TNF-a inflammatory effects in human chondrocytes244,245. BTZ has also 
been shown to improve lymphatic drainage and attenuate OA progression in rodents 
showing enhanced lymphatic drainage. Additionally, in the case of an RA-like model in 
the mouse, the overexpression of VEGF-C in the joint leads to improved clearance and 
articular cartilage health246. While it has been shown that VEGF-C can rescue lymphatic 
function in RA in vivo, critical gaps in knowledge remain, including what is the effect of 
the OA milieu on lymphatic collateralization. These data together demonstrate the 
potential of targeting lymphatics and lymphatic function as a therapeutic for joint 
diseases; however, critical gaps in knowledge remain both about the fundamental role of 
lymphatics in joint disease and how to target the lymphatics as a long term functional 





CHAPTER 3. QUANTIFYING MICROVASCULAR 
CLEARANCE USING NIR IMAGING 
3.1 Introduction 
This chapter has been adapted from the following manuscript: Doan, T. N., 
Bernard, F. C., McKinney, J. M., Dixon, J. B. & Willett, N. J. Endothelin-1 inhibits size 
dependent lymphatic clearance of PEG-based conjugates after intra-articular injection 
into the rat knee. Acta Biomater. 93, 270–281 (2019). 
The homeostatic maintenance of joint tissues and synovial fluid is regulated by 
multiple mechanisms, including blood flow, synovial permeability, capillary uptake, and 
lymphatic clearance9,101. Recent evidence has suggested that proper lymphatic function is 
critical to joint health and inflammation resolution100. During joint diseases, such as 
osteoarthritis, the production and consumption of various metabolites, including proteins, 
cytokines, and proteoglycans within the joints, are altered; understanding the clearance 
kinetics and mechanisms inform potential therapeutic delivery strategies as well as 
therapeutic targets. Cytokines and degraded ECM  during joint disease diffuse passively 
through hyaluronan lattices, the synovial matrix, and then into capillaries of the 
synovium. Low-molecular-weight molecules diffuse along their concentration gradients 
and are dominantly taken up into venous vessels247. On the other hand, high-molecular-





Much of our understanding of joint physiology and clearance relies on observations 
from several decades ago—molecules above specific molecular weights appear to clear at 
rates independent of their size, suggesting that the lymphatics are the primary route of 
clearance of large molecules from the joint220,249. Pioneering work by Simkin and 
colleagues simultaneously measured the clearance of two different sized-tracers from the 
joint to provide an indirect measurement of plasma flow and lymphatic drainage from 
knee effusions of patients with rheumatoid arthritis (RA) or osteoarthritis (OA); they 
found that clearance of proteins from the joint space is significantly slower in OA 
compared to RA218. However, all of these differential isotope studies were conducted in 
late-stage diseased patients, and 30 years later, we still do not know how these 
measurements compare to early-stage disease or healthy patients112. Recent work in 
human patients has demonstrated a decrease in lymphatic capillary density in the synovia 
of OA patients, suggesting an impairment of lymphangiogenesis6. However, in pre-
clinical studies using an injury-induced OA model in mice, lymphatic capillary density 
increased in OA animals, while the number of mature collecting vessels was markedly 
decreased in severe OA cases. More importantly, functional drainage from the knee space 
was reduced, consistent with reduced collecting vessel density and reduced drainage in 
OA11. A follow-up study found that systemic delivery of therapeutic to promote 
lymphangiogenesis could attenuate OA disease progression in this model, suggesting that 
lymphatics function and clearance mechanisms may be a promising therapeutic target 14. 
Traditionally, tools used to assess in vivo clearance kinetics from joints have relied 




measurement at various time points254. More recently, near-infrared dyes, such as 
indocyanine green (ICG)255and Cyanine 5.5, have proven to be alternatives when paired 
with sophisticated imaging hardware256. When ICG is unbound, it binds to native proteins 
and preferentially drains into lymphatics when delivered intradermally 257,258. However, 
Weiler et al.259 recently showed that repeat injections of ICG caused a reduction in 
lymphatic pump function and an enlargement of the downstream draining lymph nodes, 
while the dye itself is retained at detectable levels within the injection site for up to 2 
weeks. We have recently developed methods to quantify lymphatic pump function and 
transport non-invasively in the context of various lymphatic and inflammatory insults 
using rodent models25,257,259. 
Lymphatic vessels are known to be regulated by vasoactive peptides such as 
angiotensin, serotonin, and endothelin. Endothelin-1 (ET-1) is a soluble secreted protein 
that is a potent vasoconstrictor of blood and lymphatic vessels. For lymphatic regulation, 
ET-1 is a potent constrictor of lymphatic vessels isolated from the human thoracic duct22 
and rat mesentery260. In addition, ETb receptors are expressed by lymphatic endothelial 
cells261. Clinical evidence has shown elevated ET-1 levels in synovial fluid and is 
correlated with the severity of knee osteoarthritis262,263. Within the synovium, ET-1 can 
be expressed by synoviocytes 264. 
Articular chondrocytes can express ET receptors, and levels are increased during 
aging265,266. Further, upregulation of ET-1267 can lead to increased expression of 
metalloproteinases and thus degradation of cartilage matrix, which occurs in arthritis268. 




arthritis progression185. However, the implication for ET-1 has been mainly through a 
direct effect on chondrocytes, and a potential role in clearance mechanisms remains 
unknown. 
In Chapter 3, we applied NIR imaging technology to quantify the clearance kinetics 
of nanosized PEG-NIR conjugates from rat knees and demonstrated the effect of ET-1 on 
lymphatic and venous drainage. We hypothesized that there would be a size-dependent 
clearance of tracers from the joint space. Additionally, we hypothesized that ET-1 would 
reduce lymphatic mediated uptake while venous drainage would remain unchanged. 
Thus, the effects of ET-1 on tracer clearance may elucidate its action during arthritis 
development. 
3.2 Methods 
3.2.1 Ethical approval 
IACUC committees approved this study at the Georgia Institute of Technology 
(#A15019) and the Veteran’s Administration (#V004-15) in Atlanta, GA. Sasco Sprague 
Dawley rats (Charles River Laboratories) were used for all studies reported herein. Rats 
(between 3 and 9 months old) were age-matched for each set of experiments.  
3.2.2 Reagents 
Endothelin-1 (21 amino acids), bosentan, and BQ-123 were purchased from 





3.2.3 Synthesis of PEG-NIR materials 
2 or 40 kDa PEG amine was conjugated to IRDye 800CW NHS ester (LI-COR 
Biosciences) according to the manufacturer’s instruction (LI-COR). Briefly, a 1:8 molar 
ratio of NIR dye to PEG was incubated in Dulbecco’s Phosphate-Buffered Saline (PBS; 
Life Technologies) at pH 8.5 for 24 hours at room temperature with gentle stirring. The 
mixture was lyophilized and stored at -20oC. PEG-NIR aliquots were thawed and 
resuspended with sterile 0.9% NaCl for in vivo studies.  
Increasing concentrations of 40 kDa amine PEG reacted with a fixed 
concentration of IRDye 800CW NHS ester overnight to determine the optimal PEG ratio 
to NIR-dye reaction. The reaction mixtures were separated on 8% SDS-PAGE (Bio-Rad), 
and fluorescent images were captured using the LI-COR Odyssey Infrared Imaging 
System. Fluorescence was quantified using ImageJ software269. 
3.2.4 Hydrodynamic radius measurements 
ET-1 (Sigma-Aldrich), 2 kDa PEG, or 40 kDa PEG were suspended in PBS to a 
final concentration of 1 mg/mL. The hydrodynamic diameter was measured using 
Zetasizer Nano ZS (Malvern Instruments Ltd., United Kingdom). 
3.2.5 NIR imaging of joint clearance 
Sasco Sprague Dawley rats were anesthetized with isoflurane (SomnoSuite, Kent 
Scientific), and hind limbs were shaved. Intra-articular injections (anterior approach, 4–5 




Dickinson). All reagents were diluted in 0.9% sterile saline and co-injected with a total 
volume of 50 μL in each knee. NIR images of rat knee joints were captured using an in-
house, custom-built NIR imaging system171,257. The computer-driven system included a 
cooled EMCCD camera (Evolve eXcelon, Photometrics) attached to a stereomicroscope 
(Olympus) equipped with NIR bandpass excitation and long pass emission filters and an 
automated shutter-controlled xenon arc light-source (Sutter Instrument Company). 
Fluorescence images were captured at various time points with a fixed camera exposure 
time of 100 ms using MicroManager software270. Animals recovered from anesthesia 
before the next time point was collected (unless otherwise stated). Animals were left ad 
libitum from time of injection to time of euthanasia. 
With this in vivo NIR imaging technique, we quantified the clearance of materials 
from the knee space can. Using a custom MATLAB (MathWorks) code, the region of 
interest (ROI) for each image by isolating the 5% most intense pixels. This ROI visually 
corresponded with the size and position of the knee space. Those pixels within the ROI 
were then averaged to obtain the mean fluorescence intensity. Increasing the ROI to 10, 
15, 20, 25, and 50% most intense pixels yielded similar changes in fluorescence; 
however, this also increased the number of background (non-fluorescent) pixels and 
decreased the signal-to-noise ratio. Data points were fitted to a mono-exponential 
function (Origin software): f(t) = y0 + A e (−t/τ), where y0 is the offset, t is time, A is 
normalized fluorescence at t = 0, and τ is time constant. At a minimum, 5 data points 
were collected within the first 24 hours. The R2 ranged from 0.976 to 0.999 with a mean 




to 0.999 with a mean of 0.993 ± 0.002 for mono-exponential fits of 40 kDa PEG-NIR 
clearance. To verify the intra-articular injection technique, 2 and 40 kDa, PEG-NIR was 
injected into rat knees, and fluorescence and x-ray images were captured using In-Vivo 
Extreme (Bruker). Fluorescence was captured using a 730 nm excitation bandpass filter 
and a 790 nm emission long-pass filter with a camera exposure of 5 min. The overlay of 
the fluorescence and x-ray images showed the dye location relative to the rat hindlimb’s 
skeletal structures. 
3.2.6 Lymphatic and systemic biodistribution of particles in rat 
Following intra-articular injection of 2 kDa or 40 kDa PEG-NIR into the left 
knee, rats were asphyxiated with CO2 at 4 hours post-injection. The bladder was imaged 
in situ. Lymphatic tissues (i.e., lumbar, popliteal, and inguinal lymph nodes) and other 
systemic organs (i.e., heart, liver, lungs, spleen, and kidneys) were dissected and placed 
in 24-well plates. Fluorescence images of tissues and organs were captured using an in-
house built NIR imaging system with a camera exposure setting of 2000 msec. 
Quantification of fluorescence was performed using ImageJ software. 
To determine if 40kDa PEG-NIR was metabolized in the lymph node, the isolated 
tissues were solubilized in RIPA buffer (ThermoFisher Scientific), centrifuged at 14,000 
rpm for 10 min, and the supernatant was separated on SDS-PAGE. In addition, urine was 
collected from the bladder, centrifuged at 14,000 rpm for 10 min, diluted in RIPA buffer, 
and separated on SDS-PAGE.   




Data were represented as means ± SE. Unless otherwise stated, a one-way 
ANOVA was performed with Tukey’s honest significant difference test (GraphPad Prism 
version 6.02). A p-value less than 0.05 was considered significant. For biodistribution 
studies, a one-way ANOVA was performed with a Bonferroni test. 
3.3 Results 
Figure 3 - Synthesis of PEG-NIR conjugates. A: Representative fluorescence image of 
SDS-PAGE separating IRDye 800CW NHS ester (lower band) and 40 kDa PEG-
conjugated NIR dye (upper band). IRDye 800CW NHS ester (8.6 µM) was reacted with 
differing amounts of 40 kDa PEG and equivalent volume was loaded onto SDS-PAGE. B: 
Integrated density analysis of SDS page gel C: Representative measurement of 
hydrodynamic diameter for ET-1 (black), 2 kDa PEG (red) and 40 kDa PEG (green) using 
Zetasizer Nano ZS (n = 3). D: Representative data of normalized fluorescence for 2 kDa 
PEG-NIR resuspended in sterile 0.9% NaCl. Data points were fitted to sigmoidal function 
(solid line). The 100µM concentration (blue square) was used for in vivo studies. Similar 




3.3.1 Tracer Characterization 
To optimize the synthesis of different sized particles from the knee joint, 2 kDa 
and 40 kDa PEG’s were conjugated to near-infrared (NIR) dye via NHS ester reactivity 
with the functional amine group. A reaction ratio of 1:8 of IRDye: PEG was found to 
Figure 4 2kDa PEG-NIR clearance was distinct from dye alone clearance rate. 
Representative data points illustrated the time-dependent clearance of IRDye 800CW NHS ester 
dye alone (square), IRDye 800CW NHS ester dye in the presence of 2 kDa PEG amine without 
any reaction time (circle), and IRDye 800CW NHS ester dye in the presence of 2kDa PEG amine 
after 4 hours of reaction time (triangle). Monoexponential decay fits of the data points are shown 
for IRDye dye alone (solid line), IRDye dye in the presence of 2 kDa PEG without any reaction 
time (dashed line), and IRDye dye in the presence of 2kDa PEG after 4 hours of reaction time 
(dotted line). The conjugation of IRDye 800CW NHS ester dye to 2 kDa PEG amine was a time-
dependent reaction and thus, the clearance kinetics of PEG-NIR was altered when conjugation 
was left for 4 hours. The clearance of dye alone or dye in the presence of 2kDa PEG was similar 
and thus suggested that free PEG does not alter the dye clearance. Average time constants were 
398 min (n = 2), 435 min (n = 3) and 152 (n = 3) for dye alone, for dye with 2 kDa PEG without 




maximize PEG-NIR conjugation while minimizing free dye and unconjugated PEG 
(Figure 3A). The hydrodynamic diameters for 2 kDa PEG and 40 kDa PEG were 2.60 ± 
0.18 nm and 11.93 ± 0.33 nm, respectively (Figure 3B). The fluorescence intensities of 
PEG-NIR dyes were linear within the range of 10 - 200 µM (Figure 3C). At 
concentrations above 200 µM, the fluorescence intensity of PEG-NIR dyes decreased, 
which is suggestive of self-quenching (Figure 3D). 
3.3.2 Clearance of PEG-NIR from the knee joint 
For in vivo knee clearance studies, we injected 50 µL of 100 µM PEG-NIR (5 
nmol) into rat knees. We captured fluorescence and x-ray images of rat knees before and 
after intra-articular injection(Figure 5). The dye intensity was highest at the knee joint 
(immediately after intra-articular injection) and decreased subsequent times. Using our 
custom-built NIR imaging system, similar changes in fluorescence intensity followed 
when PEG-NIR particles were injected into rat knee joints. With this system, a camera 
exposure time of 100 msec was sufficient to assess the fluorescence change of PEG-NIR 
dyes. When the normalized averaged fluorescence intensity of the top 5% fluorescent 
pixels were plotted against time(Figure 6), the calculated knee clearance rate (τ) was 
170.7 ± 11.0 min for 2 kDa PEG-NIR (n = 10) and 243.2 ± 15.8 min for 40 kDa PEG-
NIR (n = 11; p < 0.005). The concentration and volume of tracer injected were identical; 
therefore, the difference in clearance rate was attributed to the difference in size. The 
clearance kinetics of PEG-NIR was not due to residual free or unbound NIR dye in the 




into the rat knee immediately (after mixing), the fluorescence signal remained elevated 
for more than 2 days and exhibited a slower clearance rate (Figure 4). Additionally, 40 
kDa PEG-NIR purified through a gravimetric Sephadex column showed similar kinetics 
as non-purified 40 kDa PEG-NIR. 2 kDa PEG-NIR could not be purified via gravimetric 
filtration or dialysis; hence for direct comparisons, non-purified NIR tracers were used 










with fixed number 









Figure 5 Representative images of near infrared and x-ray images of rat knees with 
40 kDa PEG-NIR. Intra-articular injection of 40 kDa PEG-NIR was administered to rat 
knee. Representative images of rat knee at various time points: before (background, bkg), 
immediately after 0, 2 and 4 h post dye injection were shown. A: X-ray images (black 
and white) and fluorescence images (pseudo-color) were captured using the In-Vivo 
Extreme imaging system. B: Fluorescence images (gray scale) were captured using a 
custom- built NIR imaging system. C: Same fluorescence images as in B with threshold 





3.3.3 Biodistribution of PEG-NIR  
Within the synovium, materials may be cleared through capillaries of venous 
vessels (for particles < 5 nm) and/or through initial lymphatics. Tissues and organs were 
isolated 4 hours post-injection, a time point where nearly two-third of injected 40 kDa 
PEG-NIR was cleared from the knee joint to determine clearance pathways of these 
different sized PEG-NIR conjugate. Fluorescence significantly increased in the left 
lumbar lymph node of rats injected with 40 kDa PEG-NIR compared to the left lumbar 
node of naive animals (Figure 7). The lumbar node is known to collect materials drained 
from the knee joint137. 
A B
Figure 6 Clearance of conjugates from rat knees. A: A representative clearance curve 
of 2 kDa (square; 1 representative curve from the 10 animals) and 40 kDa (circle; 1 
representative curve from the 11 animals) PEG-NIR from rat knees. Solid and dashed 
lines were mono-exponential fits to 2 kDa and 40 kDa PEG-NIR data points, 
respectively. B: Average time constant for 2 kDa (n = 10) and 40 kDa PEG-NIR (n = 11; 












Figure 7 Biodistribution of PEG-NIR from intra-articular injection into rat 
knees. A: Representative fluorescence images of left lumbar lymph nodes and 
bladders isolated from rats that were naïve (control) or injected with 2 kDa 
PEG-NIR or 40 kDa PEG-NIR into left knees. For the bladders, a white border 
was manually drawn, and this ROI was used to calculate the mean fluorescence 
intensity for the tissue. Mean fluorescence intensities were calculated for each 
lymphatic tissues (B) and organs (C). Significance was determined using one-
way ANOVA and post hoc Bonferroni test with calculated p values to be < 
0.001 (***) when compared to respective tissues from naïve animals. D: 
Representative image of SDS-PAGE (n = 4) loaded with solubilized left lumber 
node (left lane) and urine (right lane) from a rat intra-articularly injected with 40 




was not taken up lymphatic vessels or, if so, not retained in the lumbar lymph node. In 
addition to the lumbar lymph node, increased NIR signals were evident in the bladder for 
both 2 kDa and 40 kDa PEG-NIR administrations. No change in fluorescence was 
observed for any other tissues and organs examined, including popliteal lymph nodes, 
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Figure 8 Endothelin-1 dose-dependently inhibited the clearance of 2 kDa PEG-NIR 
from rat knees. A: Anesthetized rats were injected with 50 µL of 100 µM 2 kDa PEG-
NIR in the presence (dashed line) or absence (solid line) of 2.5 lg ET-1. Fluorescence 
images were taken every 2 min and the rats were kept under anesthesia throughout the 80 
min of data collection. B: Anaesthetized rats were injected with 50 µL of 100 µM 2 kDa 
PEG-NIR in the presence (solid circles; 1 representative study from the 6 animals) or 
absence (open squares; 1 representative study from the 10 animals) of 2.5 lg ET-1. 
Fluorescence images were taken at each time point and rats recovered from anesthesia in 
between the time points. Solid lines were mono-exponential fits for the clearance of PEG-
NIR. Horizontal arrow (single arrowhead) reflected the measured time delay, and the 
vertical arrow (double arrowhead) reflected the fold difference in fluorescence. The effect 
of ET-1 on the time delay (C), peak normalized fluorescence (D) and calculated time 
constant (E) were shown. The number of samples for 0, 25, 250, 500 and 2500 ng ET-1 
with 2 kDa PEG-NIR were 10, 6, 6, 4 and 6, respectively. Statistical significance was 
determined after performing one-way ANOVA with Tukey’s test and p values were  < 




inguinal lymph nodes, heart, lung, liver, kidney, and spleen. However, for the signal to 
accumulate in these tissues, the tracer must be retained by some mechanism, either 
intracellular uptake or retained within the ECM. Therefore the lack of signal does not rule 
out transport through these tissues. 
3.3.4 Endothelin-1 inhibited the clearance of 2 kDa PEG-NIR from the knee joint 
ET-1, a potent vasoconstrictor, was co-administered with 2 kDa PEG-NIR (Figure 
9). ET-1 (2.5 µg) significantly prevented the clearance of 2 kDa PEG-NIR for up to 100.0 
± 40.0 min (p < 0.05). ET-1 caused an increase in fluorescence within the knee space 
during this initial inhibitory phase with a magnitude of 1.63 ± 0.17 (p < 0.01). After the 
ET-1 induced inhibitory phase, 2 kDa PEG-NIR was cleared with a calculated time 
constant of 373.7 ± 32.8 min (p < 0.001). The effects of ET-1 were dose-dependent in 
vivo. ET-1 effects on peak fluorescence (Figure 8D) were significant at doses as low as 
250 ng, suggesting that this parameter may be more sensitive to capturing the biological 
effects of ET-1 than time delay or time constant.  
In a separate group of animals kept continuously under anesthesia after intra-
articular injection, the ET-1 effect on peak fluorescence was less pronounced (Figure 8A) 
than those recovered from anesthesia before collecting the next data point (Figure 8B, E). 
This finding suggests that joint distention and the subsequent convective transport and 
diffusion of ET-1 to surrounding tissues may facilitate ET-1 action. 









Figure 9 Endothelin-1 dose-dependently inhibited the clearance of 40 kDa PEG-NIR 
from rat knees. A: Anaesthetized rats were injected intra-articularly with 50 µL of 100 
µM 40 kDa PEG-NIR in the presence (solid circles; 1 representative trace from the 6 
animals) or absence (open squares; 1 representative trace from the 11 animals) of 2.5 lg 
ET-1. Fluorescence images of the knee were taken at each time point and rats recovered 
from anesthesia in between the time points. Solid lines represented mono-exponential fits 
for the clearance of PEG-NIR. The effect of ET-1 on the time delay (B), peak normalized 
fluorescence (C) and calculated time constant (D) were shown. The sample size for 0, 25, 
250, 500 and 2500 ng ET-1 with 40 kDa PEG-NIR were 11, 6, 6, 7 and 6, respectively. 
Significance was determined after performing one-way ANOVA and post ad hoc Tukey 




(Figure 9) was observed for the ET-1 effect on 2 kDa PEG-NIR clearance. The time 
delay for 40 kDa PEG-NIR with 2.5 µg ET-1 was 164.2 ± 45.2 min, and without ET-1 
was 34.5 ± 10.0 min (p < 0.001). ET-1 (2.5 µg) significantly increased the peak 
fluorescence of 40 kDa PEG-NIR from 1.16 ± 0.08 (without ET-1) to 1.85 ± 0.15 (p < 
0.001). ET-1 co-delivery led to a significantly higher time constant of 506.7 ± 40.6 min 
for 40 kDa PEG-NIR compared to 40 kDa PEG-NIR alone (p < 0.001).  
3.4.3 Specificity of ET-1 on knee clearance 
To determine the specificity of ET-1, bosentan, a competitive antagonist for both 
ETA and ETB receptors, was co-injected with ET-1 and 2 kDa PEG-NIR (Figure 10). 
Bosentan blocked the ET-1-induced changes to 2 kDa PEG-NIR clearance. The time 
constant for 2 kDa PEG-NIR clearance with ET-1 was 408.0 ± 26.7 min, and in the 
presence of bosentan, it was 153.7 ± 21.7 min (p < 0.001), a value that was not significant 
from the clearance of 2 kDa PEG-NIR alone (164.5 ± 26.9 min). Bosentan did not 
significantly alter ET-1 effects on time delay and peak fluorescence for 2 kDa PEG-NIR. 
Co-injection of an antagonist with specificity for the ETA receptor, BQ-123, also 









Figure 10 Bosentan and BQ-123 attenuated the effects of ET-1 inhibition of 2 kDa 
PEG-NIR clearance. A: Data points illustrated the time-dependent clearance of 2 kDa 
PEG-NIR without (open squares; 1 representative trace from the 4 animals) or with ET-1 
(filled circles; 1 representative trace from the 4 animals), with ET-1 and bosentan (solid, 
upright triangle; 1 representative trace from the 4 animals) and with ET-1 and BQ-123 
(solid, inverted triangle; 1 representative trace from the 4 animals). 500 ng ET-1 (0.2 
nmol) were challenged with 25 lg bosentan (43.9 nmol) or 5 lg BQ-123 (8.2 nmol). Inset, 
the effect of ET-1 antagonists on the clearance of 2 kDa PEG-NIR with a reduced time 
scale (up to 3 h). The effect of bosentan and BQ-123 on the ET-1 induced changes to 
time delay (B), peak normalized fluorescence (C) and calculated time constant (D) were 
shown. For saline, ET-1, ET-1 with bosentan, and ET-1 with BQ-123, n’s equaled 4 for 
each condition. Significance was determined after performing one-way ANOVA and post 
ad hoc Tukey analysis. Calculated values were considered significant when p < 0.05 (*) 




effects on the clearance of 40 kDa PEG-NIR. Similar to that found for 2 kDa PEG-NIR, 
bosentan and BQ-123 significantly prevented ET-1-induced change on time constant 
(Figure 11D). ET-1 shifted the time constant for 40 kDa PEG-NIR from 220.0 ± 12.8 min 
to 363.7 ± 17.2 min (p < 0.001), and with the addition of bosentan or BQ-123, the time 





Figure 11 Bosentan and BQ-123 attenuated the effects of ET-1 inhibition of 40 kDa 
PEG-NIR clearance. A: Data points illustrated the time-dependent clearance of 40 kDa 
PEG-NIR without (open squares) or with ET-1 (filled circles), with ET-1 and bosentan 
(solid, upright triangle) and with ET-1 and BQ-123 (solid, inverted triangle). 500 ng ET-1 
(0.2 nmol) were challenged with 25 µg bosentan (43.9 nmol) or 5 µg BQ-123 (8.2 nmol). 
Inset, the effect of ET-1 antagonists on the clearance of 2 kDa PEG-NIR with a reduced 
time scale (up to 5 hours). The effect of bosentan and BQ-123 on the ET-1 induced 
changes to time delay (B), peak normalized fluorescence (C) and calculated time constant 
(D) were shown. For saline, ET-1, ET-1 with bosentan, and ET-1 with BQ-123, n’s 
equaled 8, 11, 6 and 3, respectively. Significance was determined after performing one-
way ANOVA and post ad hoc Tukey analysis. Calculated values were considered 





and BQ-123 did not have a significant effect on ET-1 induced changes to time delay and 
peak fluorescence. 
3.4 Discussion 
The clearance of materials and proteins from the knee joint is critical to normal 
joint homeostasis; measurement of these processes has historically been performed using 
radioactive tracers. However, this technique requires collecting synovial fluid samples 
over time, presenting technical challenges in small animal models like rats or humans 
where large machinery is required to obtain x-ray or MRI readings. More recently, NIR 
dyes and imaging techniques have enabled noninvasive longitudinal assessment of in 
vivo clearance kinetics on a much smaller scale11,221,271,272. We employed a near-infrared 
imaging technique to assess the clearance of nanometer-sized molecules from rat knees. 
In this chapter, we utilized PEGs as NIR tracking molecules because they are hydrophilic 
and electrostatically neutral. Thus, they are not likely to bind to ECM proteins of the 
joint. 
Assessment of fluorescence signal from probes injected into the knee joint is an 
indirect measurement of knee clearance. Over time, the measured fluorescent signal is a 
net result of diffusion and equilibration of materials within the synovial fluid, IAP, 
mechanical loading, interstitial pressure due to the pressure gradient formed from the 
injection, and subsequent removal via the blood or lymphatic microcirculation. One 
finding reported in this study was the initial rise in fluorescence of either 2 kDa PEG-NIR 




increase in fluorescence is likely due to the diffusion-assisted equilibration of tracer to 
areas of synovium closer to the skin. The difference in the peak and time delay as a 
function of size also supports that this phenomenon is diffusion-driven and not due to 
other factors. It is unlikely that the rise in fluorescence is due to the dye's unquenching 
since we are using a PEG-NIR concentration within the linear range of fluorescence 
detection. Like our findings, Shi et al.12 also reported a time delay of nearly an hour for 
ICG clearance in mice knees. ICG predominantly binds to albumin since it is an abundant 
soluble protein and clear through lymphatics. Also demonstrating that the peak is a size-
dependent diffusion-driven process, 200 nm magnetic particles injected in the joint space 
present a peak intensity over 1-2 days273. 
Materials injected intra-articularly clear by a process where they diffuse through 
the synovial fluid, pass through the synovial lining, diffuse into the synovium, and are 
cleared from the joint through capillaries. These processes are effectively calculated 
together as a bulk parameter, given the inability to characterize each component. The 
calculated time constant reported herein did not include data points found in the delay (or 
lag) phase to minimize the initial diffusion differences of 2 kDa and 40 kDa PEG-NIR. 
We determined that the τ for 2 kDa PEG-NIR is about 1.4 times faster than 40 kDa PEG- 
NIR from rat knees. Previous studies have quantified the clearance kinetics of materials 
with a variety of sizes. From Shi et al.11 published work, we approximate the τ for ICG in 
mice knees at about ~140 min. Singh et al.272 calculated the half-life of 500 nm particles 




A study recently reported joint clearance and synovial transport of different sized 
dextran (10 and 500 kDa) in naïve and OA rats; clearance and synovial transport were 
slower for 500 kDa dextran transport slowed in OA221. These findings are consistent with 
the size-based clearance that we and others have found. A separate study by Loffredo et 
al.267 used heparin, a charged molecule, to retain insulin growth factors within the knee 
joint for a more extended period. Similarly, Bajpayee et al. 254 have shown that charged 
avidin conjugated to Texas Red is sequestered in articular cartilage and meniscus for days 
while neutral avidin is cleared within 24 hours. Further, the charged moieties were 
correlated to the glycosaminoglycan content of various cartilage tissues within the knee 
joints. The latter two studies injected similar-sized conjugates as 40 kDa PEG-NIR, but 
the materials had charged moieties, preventing free diffusion and clearance within the 
knee joint. These studies suggest that both size and charge play a critical role in retaining 
materials within the joint and can improve biomaterial carrier design and retention of 
drugs within the knee joint. 
Intra-articular injections are becoming a standard minimally invasive approach to 
deliver various therapeutic ranging from small molecules to cells to tissue derivatives. 
Various formulations of PEG-based biomaterials have been used as drug carriers to 
improve drug retention and to increase drug concentration within a localized area274–276. 
For example, PEG hydrogel microspheres have been used to deliver compounds 
associated with inflammation and were retained for at least a month275. These data 
suggest that increasing the PEG size into the micron range would further influence the 




mechanisms from a passive, diffusion-dominated clearance process to an active, cell-
mediated clearance process. Thus, PEG-based delivery provides a platform that can be 
tailored to many different therapeutics, and as we show here, the retention within the joint 
space and the subsequent clearance route can be controlled through simple size-
dependent mechanisms. 
The optimal hydrodynamic diameter range for uptake into lymphatics is 10–100 
nm, and anything < 5 nm is readily reabsorbed by blood capillaries113,277,278. Our finding 
in this aim is consistent with this dogma for clearance of nanosized materials into lymph 
nodes279. The 40 kDa PEG-NIR with a hydrodynamic diameter greater than 10 nm was 
found collected in the lymph node, while 2 kDa PEG-NIR (< 10 nm) was not present in 
the node. These data suggest that 40 kDa PEG-NIR is cleared by the common pathways 
through the lymphatic system, as demonstrated in the skin 115. Increased fluorescence was 
also found in the bladder when rats were injected with 2 kDa or 40 kDa PEG-NIR, 
showing that these regents can clear renally. 
Interestingly, a significantly higher amount of fluorescence was found from 40 
kDa PEG-NIR injected animals from bladders than of 2 kDa PEG-NIR injected animals. 
This may be due to a higher amount of 2 kDa PEG-NIR being excreted from the animal, 
which we did not quantify in this study. Regardless, we did not find any free dye or 
fragmented 40 kDa PEG-NIR in lymph node tissues, suggesting that only intact 40 kDa 




The role of ET-1 in joint homeostasis is largely unclear. ET-1 levels have been 
reported to be elevated in the synovial fluid of OA patients262, and further, the 
concentration of ET-1 in the synovial fluid is directly correlated to severity and stage of 
OA disease progression 280. ET-1 has also been implicated in other bone-related diseases, 
including rheumatoid arthritis and scleroderma, and abnormalities, such as craniofacial 
mandible development185. ET-1 has been implicated in increased osteoblastic activity in 
cancerous bone metastases and could be involved in the development of osteophytes in 
OA281. The repeated injection of ET-1 did not appear to have any sustained effect on joint 
clearance in these animals as only acute changes in drainage were observed, and joints 
were randomized to ensure any adverse effects of ET-1, if any, would be minimized. In 
order to understand the effects of ET-1 administration alone on joint health, studies must 
be done to assess cartilage and bone morphology after acute and prolonged ET-1 
exposure either endogenously via lentiviral administration to the joint or exogenously 
through daily injections. 
These reports have led to investigations targeting ET-1 signaling as a potential 
therapeutic in arthritis development and progression. In an OA rat model, ET-1 
antagonist BQ-123 (30 nmol via weekly intra-articular injection) was shown to attenuate 
OA progression282,283. In addition, Donate et al. 284 reported that oral administration of 
bosentan protected collagen-induced OA in rats. These antagonists prevent the 
breakdown of articular cartilage in OA since ET-1 is upregulated in chondrocytes during 




Our investigation in this chapter provides an alternative role for ET-1 in joint 
homeostasis by regulating the joint's microcirculation and clearance pathways. We 
demonstrated that intra-articular injection of ET-1 into rat knees dose-dependently and 
time-dependently inhibited the clearance of both 2 kDa and 40 kDa PEG-NIR, suggesting 
a modulation of both venous and lymphatic systems. Thus, it is probable that ET-1 has a 
general effect on the knee's microenvironment and not specific to blood or lymphatic 
pathways. Lymph formation itself is a function of the Starlings forces that drive capillary 
filtration. Thus, any factor that alters local arterial and venous pressure will likely alter 
lymph formation and lymphatic clearance. The data is unclear to what extent the 
observed changes in the clearance of the two different sized molecules result from arterial 
effects, venous effects, lymphatic effects, or some combination. Alterations in the local 
microcirculation by ET-1 reduced the clearance of both large and small molecules from 
the joint. Consistent with others, ET-1 can modulate isolated venous and lymphatic 
vessels260,285. Also, the effect of ET-1 is observed within minutes of intra- articular 
injection, suggesting that ET-1 action is within the localized knee joint. From this 
finding, we speculate that ET-1 may prevent clearance of inflammatory cytokines during 
OA, and hence, antagonists of ET-1 would improve knee clearance and thus decrease OA 
progression. 
Similarly, Karlsen et al. 286have also shown that ET-1 can delay lymphatic 
drainage from intradermal injection in mice and rats. The transient effect of ET-1 may be 
explained by its rapid clearance from the knee space since it is smaller than 2kDa PEG. 




internalization and desensitization287,288. In addition, isoflurane may influence ET-1 
effectiveness in rat knee joints. We found a decreased response to ET-1 with animals 
continuously kept under isoflurane anesthesia. Others have reported similar findings 
where isoflurane can attenuate ET-1 effects on aortic contractions289, airways of rat 
smooth muscle contraction 290, and calcium mobilization of cultured smooth muscle 
cells290. 
There are numerous small molecule inhibitors of ET-1 that are FDA-approved 
agents used for the treatment of hypertension. Bosentan, a small synthetic molecule, and 
BQ-123, a cyclic peptide, are competitive blockers of ET-1 receptors. Similar to the 
established pharmacodynamic profile for these antagonists, we found that bosentan was 
less efficacious than BQ-123, and hence, a 5.4-fold more molar amount of bosentan was 
needed to achieve a similar block of ET-1 induced effects as BQ-123. It is noteworthy 
that inhibition of ET-1 with bosentan (oral administration) ameliorates pain, 
inflammation, and severity of arthritis-induced cartilage deterioration in a rodent arthritis 
model 284. These data suggest that bosentan may improve clearance mechanisms in 
arthritic knees; improved clearance could normalize joint homeostasis and prevent the 
accumulation of inflammatory cytokines, proteases, and other mediators of disease 
progression.  
3.5 Conclusions 
In this CHAPTER, we demonstrated the use of PEG-NIR tracers for intra-




previously shown in the seminal joint clearance papers111,291. In addition, ET-1 injected 
into the knee had a drastic and dose-dependent overall drainage of tracers from the knee 
space. Given that effusions commonly manifest in OA, fluid drainage in OA may be 
regulated by microvascular agents and pathological changes in the synovial joint tissue 
structure and function. Clinical assessments are needed to understand how ET-1 secretion 





CHAPTER 4. MULTICHROMATIC NEAR-INFRARED 
IMAGING TO ASSESS INTERSTITIAL LYMPHATIC AND 
VENOUS UPTAKE IN VIVO 
4.1 Introduction 
In CHAPTER 3, we demonstrated that NIR imaging could be used to detect 
differences in clearance in the presence of a known effector of vascular function ET-1. In 
this CHAPTER, the objective was to use NIR imaging to assess venous and lymphatic 
clearance simultaneously. This chapter is adapted from the following manuscript, which 
is currently in review and can be accessed at: Bernard, F. C. et al. Multichromatic Near-
Infrared Imaging to Assess Interstitial Lymphatic and Venous Uptake In Vivo; bioRxiv 
2021.03.07.434298 (2021). doi:10.1101/2021.03.07.434298 
The circulatory system maintains tissue homeostasis by delivering nutrients and 
oxygen to the tissue space and removing proteins and waste products. Crucial to this 
process is removing interstitial fluid, proteins, and lipids by the lymphatic vasculature; 
this fluid then returns to the circulation through absorption at the lymph nodes and 
delivery to the central venous system through the lymphatic ducts128. Generally, there are 
two routes of fluid clearance from tissues: 1) venous uptake and 2) lymphatic uptake. 
Venous return in tissue beds is passive, size-dependent, and varies based on capillary 
physiology101,292. In contrast, lymphatic capillaries originate from the tissues and have 




extrinsic motion of the surrounding tissue, combined with the intrinsic contractility of 
downstream lymphatics, creates transient pressure gradients that allow fluid and 
macromolecules to enter the vessel and be transported downstream. Impaired interstitial 
fluid clearance has been implicated in various diseases, including lymphedema129, 
cancer293, and arthritis294. Techniques to measure clearance kinetics from interstitial 
spaces are critical to evaluating disease states and different tissues' ability to drain 
molecules from the interstitial spaces. These measurements have been assessed 
classically via radiolabeled agents, which carry potential toxicity and require additional 
safety measures 295–297. However, the advent of near-infrared (NIR) fluorescent imaging 
allows for cost-effective, high resolution, clinical and preclinical imaging in various 
applications298–300. 
NIR-based technologies have advanced considerably in the last decade—both in 
terms of imaging components and tracers and fluorophore-based probes—which have 
allowed for significant new in vivo capabilities. The NIR imaging window includes the 
visible and infrared light spectrum from 650-1300 nm, which due to longer wavelengths, 
penetrates tissues deeper than higher energy light301–303. Contrast agents like indocyanine 
green (ICG), polyethylene glycol (PEG) conjugated with NIR dyes, or NIR quantum dots 
have been used to visualize lymphatics and blood vessels in vivo 257,259,304–306. Preclinical 
NIR imaging has also previously enabled the measurement of tracers' differential uptake 
as a function of size from different tissue beds221,304. In addition, multichromatic NIR 
imaging (e.g., imaging with multiple NIR fluorescent probes) empowers mapping of the 




extended to differentiate between venous uptake and lymphatic uptake simultaneously in 
the same tissue bed. 
In CHAPTER 3, the size-dependent uptake of 2 and 40 kDa NIR PEG into the 
venous and lymphatic circulation was validated, and we demonstrated that the intra-
articular injection of endothelin-1 (ET-1), a vasoactive compound in lymphatics and 
veins, transiently reduced the outflow of both PEG tracers from the joint in a dose-
dependent manner. Due to these experiments' monochromatic nature, we were unable to 
assess lymphatic and venous drainage simultaneously. The inability to differentiate 
clearance mechanisms and function between the venous and lymphatic systems is a 
critical technological gap that has broad implications for many different tissues and 
disease states. Coupling in vivo delivery with multichromatic NIR imaging could allow 
for the advancement of understanding how the venous and lymphatic drainage may 
change in the context of diseases or physical interventions. The objective of this 
CHAPTER was to develop a novel technological approach that couples NIR imaging 
with the size-dependent clearance of tracers in vivo. We hypothesized that a 
multichromatic imaging approach for differentially imaging the lymphatic and venous 
systems would show the technique's utility in both the mouse tail, where the superficial 
vessels can be visualized, and assessed in the rat knee, where joint uptake occurs slowly 
and in deeper tissue structures. Additionally, we perturbed the joint microenvironment by 
exercising the rats on a treadmill and detected venous and lymphatic clearance changes 
within the knee joint. We hypothesized that exercise would increase venous and 





4.2.1 Tracers for in vivo injection 
IR Dye 800CW carboxylate (free dye) (LI-COR Biosciences) was purchased as a 
dry lyophilized powder. 20 nanomoles were resuspended in 100 µl of sterile saline to 
make a 20 mM stock solution and used within a few days of resuspension. For tail 
injections, 2.5 µl of the stock solution was used. For tissue phantom studies and knee 
injections, the stock solution was diluted to 0.4 mM in sterile saline. 
40 kDa methoxy polyethylene glycol (PEG) amine (JenKem Technology) was 
purchased as a dry lyophilized powder for PEG tracer synthesis. To conjugate 40 kDa 
PEG amine to IR Dye 680RD, 16 mg of PEG amine was reacted with 30 µl of 10 mg/mL 
IR Dye 680RD NHS ester (diluted in dimethyl sulfoxide (DMSO)) in a total of 1 mL of 
Dulbecco's Phosphate-Buffered Saline (DPBS) overnight. Unreacted IR Dye, salts, and 
DMSO were removed via centrifugal filtration using deionized water and 10 kDa 
molecular weight cutoff centrifugal filters (Amicon Ultra). After centrifugation, the 
purified tracers were separated into ten equal volumes of 100 µl and aliquoted to 1.6 mg 
of tracer per aliquot, lyophilized, and kept frozen at -20°C for long term storage. For tail 
injections, aliquots were resuspended in 100 µl of sterile saline, and 2.5 µl of P40D680 
was injected intradermally. For tissue phantom studies and knee clearance studies, 




4.2.2 Optical properties of tracers 
To quantify each tracer's absorbance in the visible and NIR range, 0.4 mM, 1 
mg/mL of the free dye, and 1mg/mL of PEG were loaded into a standard UV/vis 
spectrophotometer (Ultraspec 2100, Biochrom). The emission and excitation spectra of 
free dye and PEG were assessed using a microplate reader with filter-based emission and 
detection capabilities (Synergy H4, BioTek). For PEG and free dye, fixed emission filters 
Figure 12 a. Mouse tail injection and imaging methods. b. Intra-articular injections for 




of 720 and 840 nm were used while sweeping the excitation source from 400 – 700 and 
400 – 820 nm, respectively, to generate excitation curves. Following the excitation 
sweeps, fixed excitation wavelengths of 660 and 760 nm were used to conduct an 
emission sweep from 680/780 – 900 nm for PEG and free dye. 
4.2.3 NIR imaging setup 
Multichromatic NIR imaging was carried out using a customized NIR setup171,304. 
Briefly, the system consists of a cooled EMCCD camera (Evolve eXcelon, Photometrics) 
attached to a stereomicroscope with adjustable zoom (MVX10, Olympus), a shutter-
controlled xenon arc light source (Lambda LS, Sutter Instrument Company), and a 
manual filter wheel equipped with standard Cy5.5 and ICG-B filter cubes (Chroma 
Technology). The electronic shutter was left open during continuous imaging sessions, 
and images were acquired using MicroManager software270. 
4.2.4 Dye and tracer characterization and tissue phantom studies 
Polydimethylsiloxane (PDMS) tissue phantoms,  measuring 2 and 4 mm in 
thickness, were created using a previously described protocol257. By weight, 88.10% 
silicone elastomer base (Sylgard 184, Dow Corning) was mixed with 8.81% curing agent 
(Sylgard 184, Dow Corning), 1.76% Aluminum Oxide (Sigma Aldrich), and 1.32% 
cosmetic powder (Max Factor Crème Puff Deep Beige 42). PDMS phantoms were 
poured into plastic molds and left to cure in the oven at 60°C overnight. 
To obtain reference measurements for our NIR imagine setup, stock PEG and free 




tubes, free dye and PEG were diluted using PBS to 0.4 mM and 1 mg/mL. The tissue 
phantoms were used to demonstrate the effect of tissue depth on tracer intensity with the 
previous serially diluted samples. Each centrifuge tube was imaged with no tissue 
phantom or a 2- or 4-mm tissue phantom to simulate increasing tissue depth. Each tracer 
was diluted using the stock solution of the other tracer to quantify the sensitivity to each 
tracer in the presence of the other NIR tracer. The 2 mm tissue phantom was used to 
mimic the typical depth of the superficial collecting lymphatics in rodents. All images 
were taken with an exposure time of 50 and 5 milliseconds, respectively, for free dye and 
PEG.  
4.2.5 Tail injections to visualize and quantify routes of tracer clearance 
To visualize the tail lymphatics and blood vessels, 20 µl of 1% (w/v) Evans blue 
solution was injected into the tip of the tail of an anesthetized mouse. Evans blue binds to 
interstitial proteins and is mainly taken up by lymphatics when injected intradermally. 
Post-euthanasia, the skin was removed at the base of the tail to reveal the underlying 
vasculature. Images of the vasculature were taken using a standard color camera to 
provide a comparison with NIR images. For NIR imaging through the skin, isoflurane 
was used to anesthetize C57Bl/6J mice, and the animal was placed in a recumbent 
position (on its side). A mixture containing 2.5 µl of the free dye and 2.5 µl of PEG was 
mixed and loaded into 1 mL insulin syringes (Becton Dickinson) and injected 
intradermally into the tip of the tail. After injection, standard laboratory tape was gently 
applied to the base and the end of the tail to minimize drift from motion artifact during 




changing the filter wheel to select the appropriate filter set every 1200 frames (Figure 
12a). The free dye and PEG signal were evaluated at 50 and 20 milliseconds, 
respectively, and images were captured at ten frames per second. 
Animal care and experiments were conducted under the institutional guidelines of 
the Georgia Institute of Technology. Experimental procedures were approved by the 
Georgia Institute of Technology Institutional Animal Care and Use Committee (IACUC). 
4.2.6 Intra-articular injections for clearance 
Male Lewis rats weighing 350-400 grams were trained to run on the treadmill 
over two weeks. On day one, the rats were acclimated to the treadmill for 30 minutes 
without running. On day two, the treadmill speed was set to 5 m/min for 5 minutes and 0 
m/min for 25 minutes. The time spent running was increased by 5 minutes a day until the 
rats could run for 30 minutes on consecutive days after two weeks. Rats that failed to 
walk the targeted duration twice over the training course were excluded from the study. 
All other rats were randomly selected for the experimental procedure to either run or 
serve as controls for the study duration. Three sets of experiments were conducted with 
these two rat groups: 1) rats that did not run on the treadmill and were co-injected 
bilaterally with NIR tracers (No Running), 2) rats that were run on the treadmill for 30 
minutes before injection (Pre-Injection Running), 3) rats that were run on the treadmill 
for 30 minutes immediately after injection (Post-Injection Running).  
The day before the experiment, all rats were anesthetized, the hair was removed 
from the knees and lower abdomen, and background images of the knees were taken. 




which was maintained at 2% after induction. Tracers were injected in both knees and 
imaged at set time intervals (approximately 0, 1, 2, 3, 5, 7 12, & 24 hours) over the 
course of 24 hours.  
Animal care and experiments were conducted per the institutional guidelines of 
the Atlanta Veteran Affairs Medical Center (VAMC). Experimental procedures were 
approved by the Atlanta VAMC IACUC. 
4.2.7 Image processing and analysis 
Images captured using our custom NIR imaging system were saved in 16-bit 
depth 512 x 512-pixel TIF file format.  For both tissue phantom experiments and in vivo 
knee joint clearance experiments, the tracer's intensity in the image was quantified using 
a custom MATLAB (MathWorks) script. The ROI for each image was quantified by 
averaging the 5% highest pixel intensities. This ROI visually corresponded with the size 
and position of the knee space shown in Figure 13b. Data points were fitted to a 
monoexponential function f(t) = y0 + Ae-kt, where y0 is the offset, t is the time in hours, 
A is the normalized peak fluorescence at the maximum intensity, and k is the time 
constant. τ (tau) was determined as the inverse of the time constant. To compare each 
intervention's short-term effects, we calculated the mean change in ROI intensity over the 
first hour and subtracted the mean value of internal control rats. To determine each 
intervention's overall effects, we calculated the time constant for each runner and 
normalized it to the non-runner group's mean. 
 For mouse tail injections of NIR dyes, the filter was changed manually every 2 




(600 frames) of each imaging window were cropped. Fiji software was used to crop, 
register, and quantify regions of interest (ROIs)269. An ROI was drawn on the blood and 
lymphatic vessels to monitor the signal of free dye and PEG over the experiment. 
4.2.8 Data presentation and statistics 
All clearance data are presented as mean ± SEM. A Brown-Forsythe test was used 
to quantify if variances were significantly different. A student's t-test with a Welch's 
correction was used to compare the venous and lymphatic area under the curve and tau in 
control rats. A one-way ANOVA with Dunnett's multiple comparison test was used to 
calculate statistical significance for exercise studies.  
4.3 Results 
4.3.1 Optimization and characterization of NIR tracers using an in vitro tissue phantom 
Absorbance spectra of free dye and PEG display an absorption maximum of 765 
nm and 672 nm, respectively (Figure 13a). Emission and excitation spectra for these 
tracers also show each tracer's expected maxima referenced to the full-width half 
maximum of the filter sets on the imaging system (Figure 13b). We used tissue phantoms 
to determine the limits of detection in our imaging system as a function of concentration 
and tissue depth. Individual tracers were imaged in 1.5 mL centrifuge tubes with and 
without 2- and 4-mm phantoms. Increasing the tissue phantom thickness decreased the 
fluorescent intensity, though even at 4 mm, the dyes could be detected at a concentration 




the depth of most superficial lymphatics in rodents, this detection limit was less than 1% 
of the injection site's intensity. Notably, mixing the tracers did not affect the sensitivity to 
detect one dye when contained in the background of the other tracer (Figure 13d). 
4.3.2 NIR tracers of different size exit through spatially distinct clearance pathways 
Figure 13 Sensitivity Analysis of Near-Infrared Dyes with Tissue Phantoms 
a. Absorbance spectra show a unique absorption profile for each tracer. b. Solid and 
dashed lines show the excitation/emission spectra for 800CW carboxylate (free dye) and 
680RD 40 kDa PEG (PEG), respectively. Our NIR stereoscope filter cube setup is 
represented by the bars above the graph, showing that our optical configuration is 
designed to read each tracer’s unique signal. c. Tissue phantoms used to determine the 
effect of tissue depth on detecting free dye and PEG showed reduced intensity as a 
function of phantom depth and serial two-fold dilution. Consequentially, we were able to 
see a reduction in signal intensity below the background (dotted line) and, therefore, 
could reach the limit for these tracers at this tracer at 25 ms exposure and 100 ms 
exposure time respectively, using a 4 mm tissue phantom. d. Free dye was serially 
diluted using a stock solution of PEG and vice versa. There was no change in overall 




Figure 14 Co-injection of NIR tracers results in differential uptake of 800 CW 
Carboxylate and 680RD PEG 40 kDa Evans blue dye injected into the tail of a 
mouse immediately before euthanasia shows the concentration of Evans blue dye in the 
lymphatics (blue arrows) that flank the blood vessels (red arrows) (scale bar = 1000 
um). b. Free dye and PEG show the uptake of each NIR tracer in vein and lymphatics 
10 minutes post injection (scale bar = 1000um). c. Free dye can initially be seen in the 
lymphatic; however, over time free dye concentrates in the circulation revealing the tail 
vein. PEG shows the sustained uptake of PEG dye into lymphatics. d. Measurement of 
signal intensity over the course of the four imaging windows for each respective tracer 
shows large phasic lymphatic contractions for the PEG tracer and increasing free dye 
signal over time. 
 The mouse tail's unique circulatory and lymphatic vasculature was visualized via 
Evans blue and skin removal intradermal injection. The lymphatics immediately cleared 




the tail vein and artery (Figure 14a). To simultaneously quantify lymphatic and venous 
drainage, these tracers were co-injected in the mouse tail. Images for each tracer were 
captured during two-minute imaging windows (eight recordings per tracer). Figure 14b 
shows that the routes of clearance of free dye in the blood circulation (red) and PEG dye 
in the lymphatics (blue) 10 minutes post-injection are spatially distinct and match the 
expected physiology where two lymphatic vessels flank a blood vessel. The free dye was 
initially detected in the lymphatic within the first imaging window (Figure 14c), as the 
free dye is not expected to be excluded by lymphatics. The free dye intensity increased 
between the first, third, and fifth imaging windows and remains constant by the seventh 
(Figure 14). However, PEG entered the lymphatics after injection and did not appear in 
the bloodstream over this time interval, demonstrating the lymphatic specificity of PEG 
(Figure 14c). Also, the lymphatic tracer exhibited strong transient peaks in the signal 
intensity due to intrinsic phasic lymphatic contractions. In contrast, no such peaks were 
present in the tracer taken up into the blood circulation.  
4.3.3 Co-injection to assess differential tracer clearance in the joint 
 The effect of exercise on intra-articular clearance has not been extensively 
studied122,124, specifically in quantifying the change in venous and lymphatic drainage. 
Therefore, after confirming size-dependent uptake from the tail, we used multichromatic 
imaging to assess intra-articular drainage. Unlike intradermal injections, materials from 
the joint space clear much slower253,286,309; therefore, venous and lymphatic clearance 
from this interstitial depot was expected to occur over one day. Simultaneously injected 




followed by monoexponential clearance kinetics consistent with previously reported 
figures114. Specifically, lymphatic tracers showed a more substantial increase in intensity 
after the injection, whereas this increase was less pronounced for the venous tracer. By 12 
hours post-injection, the intensity of the free dye was not detectable (Figure 15a). The 
normalized area under the curve (AUC) for free dye was calculated to be 3.59 ± 0.18 and 
18.57± 1.33 for PEG (p<0.0001), demonstrating significant retention of the PEG in the 
joint space (Figure 15b). The time constant (Tau) for the clearance of free dye was 
calculated to be 4.28 ± 0.25 hrs, while the time constant for PEG was 7.11 ± 0.51 hrs 
(p=0.0003) (Figure 15c).  A detectable amount of the PEG tracer remained in the joint 
space even after 24 hours (Figure 15a), likely due to some PEG tracer remaining trapped 
in the interstitium.  
Figure 15 Co-injection of NIR tracers allows for the simultaneous detection of 
lymphatic and vascular mediated clearance from the joint space.  
a. Clearance profiles for PEG and free dye show the characteristic lymphatic and venous 
clearance, respectively. b. The areas under the curves show a significantly lower AUC 
for free dye compared to the PEG. c. First-order clearance constant tau was calculated 
for each tracer and is significantly higher for the lymphatic draining PEG vs the venous 




4.3.4 Multichromatic imaging for measuring patterns in joint clearance 
Rats were exercised pre-or post-injection to demonstrate the utility and sensitivity 
of multichromatic imaging to evaluate differential changes in clearance mechanisms. In 
rats that received no running intervention, clearance curves for both lymphatic and 
venous tracers had clearance profiles as expected. (Figure 16a).   Qualitatively, there did 
not appear to be differences in the traces of designated runners and control animals from 
the initial injections. Therefore, the normalized changes in fluorescence intensity were 
calculated (Figure 17a, c) and the time constant (Figure 17b, d) to quantitatively evaluate 
these differences. 
Figure 16 Clearance Profiles for PEG and free dye with running.  
a-c. Clearance profile of lymphatic specific tracer (PEG) for no running, pre-injection 
running and post-injection running experiments. d-f. Clearance profile for venous 






Figure 17 Effect of running on Normalized Change in Intensity and Normalized 
Tau. a, b. The normalized intensity was calculated to assess the transient effect of 
running on dye dispersion in the joint. For each experiment, all runners were normalized 
to the mean of non-running controls. Compared to the control experiment running pre- 
or post-injection did not significantly change the initial free dye intensity; however, at 
the second captured timepoint, post-injection normalized intensity was significantly 
decreased compared to pre-injection running (*, p = 0.04). After 1 hour, lymphatic 
intensity was significantly decreased compared to controls (*, p = 0.01) and pre-
injection running (***, p = 0.0003) c, d. Time constant (tau) for each condition was 
normalized to the controls for each day. Compared to intraexperimental non-running 
controls, there are no significant differences in clearance rate for either tracer. Compared 




For venous drainage, running pre-injection (0.26 ± 0.10) significantly increased (p 
= 0.04) the change in fluorescence intensity compared to running post-injection (-0.03 ± 
0.06), however neither were significantly different from control (0.06 ± 0.06) (Figure 
17a). Figure 17c shows the normalized tau (venous) for running post-injection was 
calculated to be (0.79 ± 0.13) which is significantly reduced (p = 0.04) the compared to 
pre-injection running (1.188 ± 0.12) (Figure 17c) however neither were significantly 
different than controls (1.16 ± 0.05).  
When assessing lymphatic clearance, we observed a significant reduction (p = 
0.0003 and p = 0.01) in the initial change in fluorescent intensity in running post-
injection (-0.19 ± 0.05) compared to pre-injection (0.36 ± 0.1) and non-running controls 
(0.20 ± 0.1) (Figure 17b). however, we did not observe any significant change in tau for 
lymphatic tracers for the various conditions of running (Figure 17d). These data suggest 
the transient effect of running may be lost over the much longer timescale for which 
lymphatic clearance occurs.  
4.4 Discussion 
In this CHAPTER, we demonstrated the ability of multichromatic NIR imaging’s 
ability to assess interstitial clearance mechanisms from multiple tissue beds. Clearance 
pathways and rates are essential in tissue homeostasis and dictate how biomolecules 
interact with their intended targets. Clearance to lymphatics or venous circulation has is 
understudied in vivo. Using tissue phantoms, we established the exposure time and tissue 
depth limitations required for in vivo multichromatic imaging and determined that 




intensity resulted from changes in concentration or position of our tracers within our 
ROIs. We then used the mouse tail, a tissue drainage bed with well-defined physiology, 
to show that we could target lymphatic and venous circulation and quantify function. 
Lastly, we demonstrated the capacity to quantitatively image routes of clearance from the 
joint space. Given our limited understanding of how exercise regulates the clearance of 
materials from the joint space, we used multichromatic NIR imaging to enable 
technology to assess lymphatic and venous drainage in that context. 
 This study demonstrated the size dependence of interstitial molecules via venous 
and lymphatic pathways; however, the first to demonstrate this via simultaneous imaging. 
Proulx et al. showed that NIR tracers that clear through lymphatics have a delayed uptake 
into the systemic circulation compared to molecules that drain directly into the blood 
stream305. In our mouse tail study, the free dye intensity in the blood ROI is initially low. 
That signal intensifies in the tail vein over time, likely due to a renal clearance not 
surpassing the intradermal depot clearance over this total imaging window310. Thus, this 
dye's intensity in the blood circulation continuously increases as the concentration 
delivered to the blood over time increases. In addition, the PEG tracer signal intensity 
traces exhibited the characteristic phasic contractions attributed to lymphatic pumping. 
Therefore, our mouse tail experiment validated our two tracers' size-based partitioning to 
distinct routes of clearance. 
The joint space is a unique interstitial space comprised of synovial fluid—
hyaluronic acid, lubricin, and filtered serum—that hydrates the joint tissues and buffers 




must diffuse through the synovial fluid, then into the synovial membrane. The synovial 
membrane is a specialized tissue that retains the synovial fluid while also housing the 
venous and lymphatic fluid exchange machinery to clear solute from the joint25,100. 
Smaller materials can more easily diffuse through the synovial fluid matrix and thus exit 
the joint space faster86. Larger molecules can more easily entangle in the synovial fluid 
matrix and therefore have longer residence times within the joint space312. Using 
multichromatic imaging with sized tracers enables quantifying venous and lymphatic 
clearance kinetics in the joint, simultaneously rather than separately, as done in the 
previous studies221 and furthers the ability to determine the relationship between 
lymphatic and venous uptake in vivo. 
Previous studies have shown that exercise increases interstitial125, venous313, and 
lymphatic127 flow to the muscle. In this study, we used exercise as an intervention to 
demonstrate the sensitivity of multichromatic NIR imaging to measure changes to venous 
and lymphatic clearance. In the joint space, exercise and joint loading have increased 
intra-articular pressure and cartilage flux. In this study, we showed that injection 
followed by exercise transiently increased lymphatic outflow from the joint; however, 
exercise did not significantly affect venous clearance. Interestingly, running pre-injection 
led to delayed clearance of both free dye and PEG, as exhibited by the presence of a 
larger peak intensity from the joint than their respective controls, which could be a 
consequence of altered hydrodynamic forces or delayed dye dispersion. Additionally, it 





Our current setup limited our temporal sampling frequency in both in vivo 
experiments. For running experiments, sampling frequency was limited by the time 
required for an animal to recover from and back under anesthesia. An ideal setup would 
be a wearable sensor that would go around the knee, which allows us to see the 
concentration in real-time without anesthesia. Similarly, in capturing the routes of 
clearance in the tail, we could only use one channel at a time due to our stereoscope's 
filter imaging limitations. Two cameras and light paths, or a computerized filter wheel, 
would simultaneously assess these two tracers with higher temporal frequency to quantify 
the relationship between vascular and lymphatic uptake in vivo. Additionally, the tracer 
sizes were designed to evaluate the particulate transport within the fluid; however, there 
are also cell-mediated mechanisms by which transport occurs in vivo, which could be 
imaged using these multichromatic approaches. 
4.5 Conclusions 
In this CHAPTER, we demonstrated the joint space is a well-regulated tissue bed 
that only allows for modest changes in lymphatic outflow during exercise. The 
observations in this CHAPTER are important because it shows that differential outcomes 
in lymphatic and venous clearance could be measured. Multichromatic NIR imaging can 
simultaneously image lymphatic and venous-mediated fluid clearance with great 
sensitivity and can be used to measure transient changes in clearance rates and pathways. 






CHAPTER 5. QUANTIFYING THE ROLE OF 
MICROVASCULAR CLEARANCE IN OA 
5.1 Introduction 
CHAPTER 3 and CHAPTER 4 showed that joint transport could be modulated by 
exogenous stimulation with endothelin-1 and increased physical activity. In CHAPTER 
5, we will apply NIR imaging in the context of OA using the MMT model in rats. 
Joint clearance and biodistribution have traditionally been assessed using 
radiolabeled molecule tracking and fluorescence imaging314–316. The rate of clearance of 
key SF components such as proteoglycan subunits, hyaluronic acid (HA), inflammatory 
cytokines, and growth factors from the synovial cavity is relatively slow, clearing at rates 
comparable to conditions of clearance and drainage through lymphatics317–319. In OA, 
there is evidence of an increased breakdown of macromolecules like HA, potentially 
leading to altered clearance rates, fluid turnover, and drainage into the lymphatics320,321. 
Although lymphatics are in most tissues, their involvement in the pathogenesis of 
diseases has been historically understudied. More recently, lymphatic dysfunction has 
been implicated in the progression of various diseases, including heart disease322, cancer, 
and arthritis (RA and OA)6. In OA, changes in lymphatic vessel density in the synovium6 
have been shown in late-stage OA. Wallis et al. looked at the differences in clearance 
between those with OA and RA synovial effusions and determined that radiolabelled 




serum albumin (RISA) was significantly slower, suggesting that protein trafficking is 
altered in certain issues253. Myers et al. showed that RISA clearance was increased in 
canine joints with MCL transection compared to contralateral non-operated limbs 12 
weeks post-surgery. Albumin is cleared mainly through the lymphatic system and 
albumin in normal tissues and acts as the central oncotic pressure driver323–325. In 
diseased tissues, a change in albumin clearance could signal changes in fluid transport or 
alternations in microvascular permeability of the venous or lymphatic system. 
Additionally, given that materials can exit the joint via two paths, the relationship 
between venous and lymphatic clearance in OA is still not well understood. Quantifying 
these interconnected drainage mechanisms via appropriately sized NIR tracers in a post-
traumatic model of OA would allow us to better understand this missing link.   
In musculoskeletal disease, walking exercise has been shown to improve patient 
self-reported pain and functional outcomes17. However, to date, minimal studies have 
been done to assess the effect of exercise on clearance in vivo. Previous research has 
shown that low, moderate, and high exercise regimes do not significantly impact cartilage 
but positively affect weight, a known modulator of OA risk18. Body weight-supported 
treadmill training has been shown to reduce cartilage degradation after PTOA 
development in rats suggesting that moderate exercise has beneficial effects in the 
development of OA15. Bodyweight-supported treadmill walking protected the cartilage 
more than treadmill walking alone; however, both significantly improve cartilage 
outcomes on PTOA15,326. However, what is unknown is how the timing or duration of 




In this CHAPTER, we will use exercise not as a treatment but as a mechanism to perturb 
the joint space during OA development to understand how exercise could be altering 
venous and lymphatic drainage clearance. 
The first objective of this CHAPTER was to assess venous and lymphatic clearance 
as a function of time in surgically induced OA. We hypothesized that lymphatic-mediated 
clearance of PEG would decrease with OA progression and that venous clearance would 
remain unchanged. The secondary objective of this CHAPTER was to assess the 
contribution of exercise to venous and lymphatic clearance during the development of 
OA. We hypothesized that a treadmill exercise with MMT surgery would increase the 
overall clearance of tracers from the joint space. 
5.2 Methods 
5.2.1 Synthesis of PEG-NIR materials 
40 kDa PEG IRDye 680RD (PEG) and IRDye 800CW (free dye) were 
synthesized and prepared as previously decreased in 4.2.1. 
5.2.2 MMT and Sham surgery 
The medial meniscal transection (MMT) is a surgical procedure to destabilize the 
rat knee joint and replicates osteoarthritis pathology in rodents (Figure 18). Briefly, 
animals were anesthetized via isoflurane inhalation, and the surgical site was shaved and 
sterilized immediately before surgery. Sustained Release buprenorphine (0.03 mg/kg) 




tissue incision were made along with the sterile surgical site of the left medial hindlimb, 
along the femora-tibial joint. A blunt dissection exposed the medial collateral ligament 
(MCL), which was transected to expose the meniscus. For MMT animals, the meniscus 
was entirely cut through at the narrowest point. For Sham animals, only the MCL was 
transected, and the meniscus was left intact. Soft tissues were closed with 4.0 vicryl 
sutures, and the skin was closed with staple clips. The contralateral right hindlimbs were 
unoperated and served as naïve controls herein. Post-surgery, animals were rehydrated 
Figure 18. MMT Surgery and Histopathology during different stages. a) MMT 
surgery involves the transection of MCL and meniscus while the Sham surgery only 
involves MCL transection. b) Safrinin-O staining of Naïve, Sham, and MMT animals at 
Early, Mid, and Late Stage OA reveals progressive changes in cartilage anatomy as OA 




with 10 mL of Lactated Ringer’s solution. All animals were monitored for three 
consecutive days post-surgery. Staples were removed one week after surgery when the 
skin had fully closed and healed. NIR Clearance was assessed at three weeks, six weeks, 
or nine weeks via PEG and free dye co-injection. All procedures followed institutional 
guidelines set by the Atlanta Veterans Affairs Medical Center (VAMC) and were 
approved by Institutional Animal Care and Use Committee (IACUC).  
5.2.3 Exercise + MMT Surgery 
Twelve-week-old male Lewis rats (Charles River) were acclimated for one week 
post-arrival and trained to run as previously described in section 4.2.6. On day one, the 
rats were acclimated to the treadmill for 30 minutes without running. Running was 
gradually increased to 30 minutes on consecutive days after two weeks. Rats that failed to 
walk the targeted duration twice over the training course were excluded from the study. 
All other rats were randomly selected for the experimental procedure to either run or 
serve as controls for the study duration. Knee joint clearance was measured at baseline 
(before surgery) and at weeks one, three, and six post-surgery in the rats. All rats in this 
experiment received MMT surgery. No rats walked on the treadmill as a daily therapeutic 
exercise. On each testing date, rat knees received intra-articular injections of a 
carboxylate modified IRDye800CW and IRDye680RD with 40 kDa polyethylene glycol. 
NIR images were collected immediately and out to 24 hours after injections. Rats were in 
two groups: sedentary or exercised. Sedentary rats remained within their cages 
throughout the experiments. Exercised rats underwent treadmill walking (10 m/min for 




of the time-intensity data. Rats designated to walk but failed to walk excluded on a 
particular day were excluded from that experiment’s analysis. 
5.2.4 Image and Data Analysis 
Images were analyzed using the MATLAB code referred to in 4.2.7 to assess the 
top 5% most intense pixels in each image at each time point. 
5.2.5 Data analysis and presentation 
 Each group’s surgical leg was compared to its internal contralateral control in a 
paired t-test analysis and graphed as such to assess the effect of MMT and Sham 
surgeries on NIR clearance of venous and lymphatic draining tracers. This was performed 
at early, mid, and late-stage time points. To assess the effect of exercise vs. remaining 
sedentary on joint clearance post-injection in the MMT, we compared surgery legs to 
non-surgery legs and running legs to non-running legs using a one-way ANOVA. For 
running studies, clearance data are presented as mean ± SEM. A Brown-Forsythe test was 
used to quantify if variances were significantly different.  
To understand the longitudinal effect of OA surgery on joint clearance, we 
performed Dunnett’s test to understand the effect of Sham and MMT surgery over time in 





5.3.1 Effect of MMT Surgery on Venous Clearance 
 Using the MMT and Sham models to compare the effect of surgical insult on 
clearance from the joint space, we either co-injected NIR tracers or tracked the tracers 
individually a week apart. Tau is inversely proportional to the rate of clearance, and these 
values are presented in Figure 19. For Sham limbs, tau significantly decreased three 
weeks post-surgery (162.4 ± 53.07 min vs. 116.6 ± 42.21 min, p = 0.0330). However, for 
mid and late-stage clearance, Sham clearance was not significantly different from 
Figure 19 Venous Clearance During OA Progression.  Exponential clearance of free 
dye was analyzed for Sham rats. Tau decrease in Sham animals at early-stage and by 
mid-stage and late-stage venous clearance was not signficantly different for Shams. Tau 
increased for MMT animals at early like the Shams however, at mid-stage OA tau 
remains elevated. Statistical significance was determined via a paired t-test and p-values 
< 0.05 (*) or  ≤ 0.01 (**) were noted as significant. 














































































contralateral control legs. For MMT rats, venous clearance was also significantly 
increased 3-weeks post-surgery as represented by decreased tau (154.6 ± 60.74 min vs. 
91.43 ± 23.3 min p = 0.0169). However, for mid-stage venous tau, MMT clearance joints 
remained decreased (153.1 ± 40.05 min vs. 106.9 ± 26.87 min, p = 0.0083), and by the 
late stage, MMT joint venous clearance was not significantly different from its respective 
contralateral control. 
5.3.2 MMT Surgery reduces lymphatic clearance in late-stage OA 
  Lymphatic clearance was assessed at early, mid, and late-stage MMT (Figure 
20). Tau significantly increased at mid-stage (277.1 ± 214.0 min vs. 482.1 ± 254.3 min, p 
= 0.0045) for Sham legs but was not significantly different at early and late-stage MMT. 
However, mid-stage lymphatic clearance significantly decreased compared to its 
Figure 20 Lymphatic Clearance during OA Progression. Lymphatic clearance for 
early mid and late stage for sham. Tau increased for Sham animals at mid stage, however 
Tau is not significantly diffeerent at late stage for Sham. Lymphatic clearance for MMT 
rats compared to their respective contralateral controls shows decreased tau at late stage 
for MMT animals. Statistical significance was determined via a paired t-test and p-values 
< 0.05 (*) or  ≤ 0.01 (**) were deemed significant. 













































































respective contralateral control (340.7 ± 197.7 min vs. 513.6 ± 305.7 min, p = 0.0352). 
Lymphatic clearance for MMT animals was not significantly different between 
contralateral controls at the early and mid-stage. However, at a late stage, MMT was 
significantly increased compared to contralateral controls.  
5.3.3 Venous clearance during early, mid, and late-stage OA 
To assess the effect of exercise on joint clearance, MMT animals were exercised at 
























Figure 21 Exercise increases joint clearance at mid stage OA. To assess the effect of 
running on venous drainage during OA progression Tau was assess as a function of MMT 
surgery and comparisons were made between non-runners and runners. In contralateral 
limbs there wasn’t an effect of running on Tau is previously shown in chapter 4. However 
for MMT animals running at week 6 decreased Tau. Lymphatic clearance shows 
increased PEG tracer clearance at week 6 for runners. Statistical significance was 
determined via two-way ANOVA with a Šidák comparison and p-values < 0.05 (*) or  ≤ 




measurements were assessed (Figure 21). Surgical and non-surgical legs were compared 
to their respective running or non-running controls at each time point. Running had no 
significant effect on clearance until week 6 for both venous (1.84 ± 0.17 hrs vs. 1.61 ± 
0.21 hrs, p = 0.02) and lymphatic clearance (5.42± 0.33 hrs vs. 4.40 ± 0.58 hrs,  p = 
0.006). 
5.4 Discussion 
In this CHAPTER, we used NIR imaging to understand how intra-articular 
clearance changes over time in this model. We implored multichromatic imaging to 
assess both the changes in clearance as a function of surgical insult and then in the MMT 
alone to discern the effect of exercise with disease progression. We determined that 
surgical insult from the Sham was significant to change venous and lymphatic clearance; 
however, we showed the impact of MMT on lymphatic clearance developed later. 
The synovial fluid is a complex biological solution composed of macromolecules, 
nutrients, and waste. The main constituents of synovial fluid are GAGs and 
proteoglycans, serum proteins, and water. The synovium reflects hyaluronic acid through 
size exclusion and proteoglycans and GAGs present in the extracellular spaces75. This 
helps to maintain interstitial fluid hydration and pressure. Clearance from the joint is 
mediated by blood and lymphatic capillaries327. Contained within that fluid are molecules 
that range in size from ~ 1 nm to ~200 nm110. Molecules that can escape reflection from 




nm tend to be cleared mainly through venous circulation, while molecules 10 nm and 
larger are cleared through lymphatic circulation247,253,328.  
Intra-articular pressure during rest and movement are vastly different. Intra-
articular pressure is slightly sub-atmospheric during rest and supra-atmospheric during 
joint loading329. Hydraulic conductance through the synovium increases with increasing 
intra-articular pressure330. The relationship between intra-articular pressure and arthritis 
pain/severity has been explored in a few contexts, and generally, arthritis has been 
associated with increased IAP329,331. Additionally, the hydraulic conductance of the 
synovial membrane has been explored and has been shown to increase with increasing 
OA severity in a preclinical model of OA332. These factors combined could lead to 
increased flow in the context of externally applied forces during exercise in OA. 
 To understand the longitudinal effects of OA on clearance, we conducted Sham 
and MMT surgeries and quantified venous and lymphatic tau for surgical legs and non-
operated contralateral controls. Sham animals had faster clearance for venous clearance at 
week 3, but by week 6, clearance was not significantly different. Additionally, Sham 
animals had slower lymphatic drainage at week 6 but not at week 9. We also 
demonstrated increased venous clearance at week 3 and week 6 for MMT animals and 
delayed lymphatic drainage at week 9. Specifically, a return to baseline for venous 
clearance seemed to coincide with the onset of slower lymphatic drainage. This 
potentially suggests that increases in venous clearance may partially offset the onset of 
the delay in clearance. Joint filtration and venous uptake may play a role in lymphatic 




However, after surgery, we demonstrated that regardless of treadmill running, 
venous clearance was increased compared to baseline values. This increase could be 
attributed to a variety of factors. Surgical insult via this PTOA MMT model has been 
shown to increase angiogenesis that peaks two weeks post-surgery and returns to 
baseline/control values four weeks post-surgery333. These values partially coincide with 
our measurements with increased clearance at one- and three-week post-surgery and 
return to baseline at 42 days333. Additionally, PTOA Sham surgery is associated with 
increased venous clearance at three weeks, returning to baseline at six weeks. 
Additionally, changes in IAP could result in increased outflow and hydraulic conductance 
through the synovium. 
In contrast to venous clearance, lymphatic clearance is unchanged in contralateral 
joints over this study's time course. Therefore, increases in angiogenesis could counteract 
any increases in fluid accumulation from inflammation. In this paper, we specifically 
targeted materials that clear through the fluid phase. Mwangi et al. 221 showed that 500 
kDa dextran clearance through the synovial was decreased in the MMT model. However, 
our PEG tracer is less likely to get reflected/entrapped within the extracellular matrix as 
the hydrodynamic radius is three times larger than our PEG construct334. Additionally, in 
that study, only the advective fluid movement was quantified, and the relationship 
between exercise and the movement of a larger molecule like 500 kDa Dextran has yet to 
be established. 
Increases in angiogenesis could lead to leaky venous return or changes that could 




we did not observe the direct uptake of tracers into the bloodstream or lymphatics. We 
observed the disappearance of tracers found to clear via venous and lymphatic paths in 
healthy tissues. However, in unhealthy tissues, there could be changes in the permeability 
of the vasculature that alter the traditional size partitioning effects that occur in healthy 
tissue. In other contexts, the chemical modification of the extracellular matrix can change 
the rate at which materials move without affecting the bulk mechanical properties of the 
tissue108. For example, the trans-synovial flow rate increases the clearance of hyaluronic 
acid from the joint space, meaning that the running intensity could potentially modulate 
how quickly things clear from the knee joint108. 
Our exercise study determined that exercise increased venous and lymphatic 
clearance at 6 weeks post-surgery, but exercise had no effect 1 and 3 weeks post-surgery. 
MMT surgery could modulate the protein concentration in the synovial tissues by 
increasing catabolism through inflammatory mediators, and these changes could drive 
this increased flow in the context of exercise51. Changes in clearance from the joint space 
could also dictate how injectables in the joint space perform at various stages. For 
example, delivering small therapeutic peptides into the joint immediately in a post-
traumatic insult could result in quick clearance of the therapy. Clearance must be factored 
into the treatment strategy to maximize outcomes in vivo. 
5.5 Conclusions 
This study is the first investigation to assess venous and lymphatic drainage during 




venous clearance preceded decreases in lymphatic drainage in Sham and MMT animals 
and that the onset of changes in lymphatic changes was offset by three weeks for MMT 
animals. These findings are an essential first step in understanding how post-traumatic 
OA could affect tracer clearance. More extended studies need to be done to understand 
the long-term effects of surgery on tracer clearance. 
In our second study in this CHAPTER, we investigated the effect of running from 
joint clearance at 1, 3, and 6 weeks post-MMT and observed improved clearance of 
tracers 6 weeks post-surgery in surgical limbs. It is important to note that we did not 
assess exercise's effect as a daily intervention in this model but only exercise at well-
defined points. There is a chance that exercise as a treatment could modulate 
inflammatory activity and restore joint homeostasis. These potential effects should be 





CHAPTER 6. USING EX VIVO PLATFORMS TO ASSESS 
LYMPHATIC CONTRACTILITY AND LYMPHANGIOGENESIS  
6.1 Introduction 
This CHAPTER has been modified in part from the following manuscript: 
Michalaki, E. et al. Effect of human synovial fluid from osteoarthritis patients and 
healthy individuals on lymphatic contractility. bioRxiv 2020.12.02.408294 (2020). 
doi:10.1101/2020.12.02.408294  
In CHAPTER 5, we showed that microvascular clearance was altered in PTOA. 
However, it is unknown if the loss of function is simply from decreased permeability of 
the synovium as demonstrated by Mgawi et al. 221, changes in lymphatic vessel density,  
reductions in downstream lymphatic function, or a combination of all three. The extent to 
which the lymphatic system is affected by factors draining from the SF remains 
unknown. Lymphatic vessels are responsible for maintaining the joint space homeostasis; 
therefore, efficient transport of lymph from the joint space into lymphatics is a well-
established part of joint homeostasis149. As joint inflammation is one of the leading 
drivers of OA, it is unclear what effect the OA synovial fluid may have on mature 
lymphatics within the synovium. As OA develops and progresses, inflammatory 
cytokines and by-products of the injury and degradation of articular tissues build up in 
the SF, providing a feedback system to exacerbate disease318. Thus, the lymphatic system 




homeostasis335. However, as described in earlier chapters and demonstrated in 
CHAPTER 5, there is stronger evidence that the lymphatics can become dysfunctional 
during OA6,10,12,13. In response to injury/inflammation, mature (precollecting and 
collecting)lymphatic vessels can collateralize and grow new vessels to improve flow 
around an obstruction or injury182. While a growing body of evidence implicates a critical 
relationship between OA and the lymphatic system, the related studies have mainly 
consisted of observed differences in lymph flow and the rate of fluid drainage between 
healthy and OA knee joints6,11,336. First, Wilkinson et al. demonstrated LVs in human 
synovial tissue, while subsequent studies showed differences in the number and size of 
the lymphatic vessels found in the joints11,337. When lymphangiogenesis was inhibited 
using VEGR3 neutralizing antibodies in a mouse model of OA, there was reduced 
synovial drainage and worsened disease progression14. Given the results from CHAPTER 
5 and research from other groups, lymphatic dysfunction may exacerbate OA 
development and progression. Although there is evidence of a correlation between the 
lymphatic system and OA, the specific role of inflammation on lymphatic function is not 
fully explained. 
 SF is a viscous fluid found in the cavities of synovial joints functioning as a 
biological lubricant and a means for nutrient and cytokine transportation94,338–340. 
Multiple inflammatory and anti-inflammatory molecules secreted from joint tissues and 
discovered in the SF of diseased OA patients directly indicate their role in OA 
development341,342. Patients with OA have elevated prostaglandins (PGE2), leukotrienes 




IL-6, IL-15, IL-17, IL-18, and tumor necrosis factor α (TNFα), along with the anti-
inflammatory cytokines, IL-4, IL-10, IL-13, can induce cartilage degradation and 
collagen destruction and have thus been directly implicated within the progression of OA 
341,343–346. Additionally, OA patients have shown elevated levels of the transforming 
growth factor β (TGFβ), fibroblast growth factors (FGFs), nerve growth factor (NGF), 
and vascular endothelial growth factor (VEGF) in SF, chondrocytes, subchondral bone, 
and serum 343,347,348. Notably, the increased expression of VEGF, a growth factor known 
to regulate vascular permeability and angiogenesis, has implicated the potential 
involvement of both the blood and lymphatic vasculatures in OA disease347,348. Notably, 
the known effect of age on both lymphatic contractility and synovial permeability and 
OA disease serves as an additional indication of a potential correlation between 
lymphatics and OA349–351. As products from the joint are cleared into the lymph fluid, 
chemokines may affect the LVs through direct signaling or by activating immune cells. 
However, the direct effect of SF exposure on LV contractility still remains unknown. 
Recent technological development of ex vivo lymphatic pressurization and perfusion 
systems have allowed rigorous analyses of lymphatic contractile behavior under varying 
conditions of flow, pressure, and exposure to biochemical factors142–144,146. The primary 
objective of this chapter is to use an ex vivo lymphatic pressurization device to investigate 
how lymphatic contractility changes in response to OA development in rodents and also 
in response to the simulated drainage of OA synovial fluid. 
While downstream pumping lymphatic capacity is important in joint homeostasis, 




can get transported down into the joint. Lymphangiogenesis is a complicated process by 
which new lymphatics grow from existing lymphatics, including the lesser-studied 
mature lymphatic vessels which reside within the synovium. Reduced growth from initial 
lymphatics, collecting lymphatics, or both may be responsible for changes in lymphatic 
function in vivo. To study lymphangiogenesis in vitro, two-dimension cell culture of 
lymphatic endothelial cells allows for specific investigations about mitosis, migration, or 
cell health33,169,352. However, 2D culture systems are limited because the LECs are not 
exposed to similar mechanical and cellular stimuli as in vivo. Additionally, without 
lymphatic muscle cells or fibroblasts, lymphatic endothelial cells may respond differently 
than they do in vivo353. Therefore, three-dimensional culture systems for lymphatic 
studies have been used to understand lymphatic migration, test lymphangiogenic 
potential, and understand what roles soluble factors play on lymphatic sprouting37,38,354. 
Recently the PEG hydrogel has been used to show the effect of biochemical and 
mechanical stimuli on collecting vessel segments in culture. To date, only one group has 
studied the ex vivo culture of mature lymphatic collecting vessels in hydrogel systems38. 
Bruyere et al. used a standard collagen platform to understand the biochemical factors 
that drive lymphangiogenesis ex vivo. One of the advantages of the PEG platform is the 
fine control over the ability to tune, mechanical properties (stiffness and diffusivity), 
biological signals (adhesion peptides, mitogenic factors), and degradability (enzymatic or 
hydrolytically 100% to 0% degradable), and these parameters are independently 
tunable355–357. In the case of the collagen gel, hydrogel stiffness cannot be uncoupled 




source is rat tails; therefore batch to batch variability can affect the mechanical properties 
between lots or vendors359. Given the understudied nature of mature collecting vessel 
lymphangiogenesis, the PEG hydrogel platform could allow us to study lymphatics in 
simulated pathological environments ex vivo. 
 VEGF signaling plays a critical role in lymphangiogenesis and the ability of 3D 
organoid systems to be used to interrogate critical regulatory components of VEGF 
signaling. Epsins are endocytic adaptor proteins necessary to internalize and degrade 
VEGF receptors during VEGF signaling33,157,165,166,360–362. In the contexts of diabetes, 
cancer atherosclerosis, three diseases with significant inflammatory components, epsin 
down-regulation via endothelial cell or myeloid-specific epsin 1 and 2 deletions improve 
disease phenotypes and improve angiogenesis and lymphangiogenesis33,170,362. However, 
given the high expression of VEGFR3 in the initial lymphatics and the low expression in 
collecting vessels, it is still unknown whether epsin deletion in mature vessels has a 
similar effect as in initial lymphatics30.  
In this CHAPTER, we utilized an ex vivo syringe-controlled lymphatic perfusion 
system device to study the effects of OA on lymphatic collecting vessel function under 
two conditions: 1) after MMT induction, or 2) with a simulated OA synovial fluid 
(OASF) drainage. We hypothesized that the pump function of lymphatic vessels draining 
the joint could be directly compromised in both cases due to factors within OASF and 
thus might present a therapeutic target in OA. Additionally, we investigated 
lymphangiogenesis in two contexts, 1) in the context of a simulated OA environment 




hypothesized that OA synovial fluid would decrease lymphatic growth compared to non-
OA controls. Lastly, we hypothesized that epsin deletion would improve collecting 
lymphatic vessel sprouting and could be a suitable target for lymphangiogenesis from 
mature lymphatics in vivo. 
6.2 Methods 
6.2.1 Rat and Isolated Vessels Preparation 
 Male Lewis rats 350-400 g (Charles River Laboratories, Wilmington, MA) were 
used for all experiments. For isolation of segments of femoral LVs, the animals were 
euthanized via CO2 gas. For the isolation of rat femoral LV (RFLV), the skin and 
superficial fascia layer were quickly removed to expose the area between the saphenous 
artery and inguinal ligament of the internal surface of the thigh (Figure 22). They were 
Figure 22 Rat femoral lymphatic vessel isolation. Evans blue (1% (w/v)) was injected 
intra-articularly into the left knee for visualization purposes. The immediate uptake of 
Evans blue by the lymphatics allows us to visualize the LV. The isolated RFLV is found 




handled gently to prevent bleeding and placed aside to provide access to the femoral 
lymphatics, located alongside the femoral vein epigastric artery and vein was carefully 
teased from adjacent tissue and kept together between the femoral and superficial caudal 
epigastric artery junction iliac-femoral artery (Figure 22). During the dissection, the area 
of interest was kept moist with DPBS. Suitable LVs were found along these vessels. 
Sections of the RFLVs ∼0.5 cm long were dissected, cleaned from connective tissue, and 
placed in a warm (37 °C) bath of albumin enriched physiological salt solution 
(APSS)23,144 for MMT studies and  DMEM/F12 for (ThermoFisher Scientific; 11039047) 
that was pH adjusted to 7.4 in 5% CO2 incubator. For PEG hydrogel experiments, the 
lymphatic segments were stored in 10% FBS supplemented EBM and cut into roughly 
300-micron long segments. 
6.2.2 Epsin double knockout mice generation 
The Chen group provided adult inducible epsin double knockout mice from 
Boston’s Children Hospital. Briefly, this genetic model consists of a constitutive global 
deletion of Epsin 2 coupled with a lymphatic endothelial cell-specific epsin deletion 
driven by Prox1-Cre-ERT2 via the administration of 4-hydroxytamoxifen (tamoxifen). To 
administer tamoxifen, it was first dissolved in DMSO at 5 mg/mL and kept at -20°C. For 
epsin mouse studies, mice 6-16 weeks old were given 0.3mg/30gram of bodyweight 4-
hydroxytamoxifen every other day for 16 days. To confirm that epsin deletion post-
tamoxifen treatment, flank lymphatic vessel segments were encapsulated in PEG 
hydrogels and stained for epsin 1(1:50 dilution, Santa Cruz Biotechnology, Inc) using the 




6.2.3 Synovial Fluid Collection 
 In this study, the effect of three types of SF was investigated: healthy synovial 
fluid (HSF), a mixture of synovial fluid derived from various OA patients (OASF-pool), 
and synovial fluid derived from one specific OA patient (OASF#3). HSF was purchased 
from Articular Engineering (Northbrook, IL; Donor ID Number: SF-1435). OASF was 
collected from knee OA patients receiving arthrocentesis (joint aspiration). Patients were 
recruited from Emory University Sports Medicine under an Institutional Review Board 
(IRB) OA protocol; all patients gave informed consent. OASF was directly removed from 
OA patients by an orthopedic physician. SF samples were kept frozen in 1 mL aliquots at 
-80 °C until use. For all sprouting experiments, SF was diluted in a 1:20 or 1:10 ratio 
with EBM, and for all the perfusion experiments, SF was diluted in 1:10 DMEM/F12. 




Cytokine content of all SF samples was quantified using a bead-based multiplex 
immunoassay, Luminex Cytokine/Chemokine 41 Plex Kit (EMD Millipore Corporation, 
Burlington, MA; HCYTMAG-60K-PX41) (Figure 23). Median fluorescent intensity 
Figure 23 Cytokine profile for OASF and HSF. The relative concentration of 41 
cytokines were measured in OASF#3, OASF-pool, and HSF using a multiplex 
immunoassay, LUMINEX. The data were normalized based on the corresponding 
background measurement, obtained from a LUMINEX run with only assay buffer, and 
presented based on a heat map where blue cells indicates a lower value while red cells 




values were read using Luminex xPONENT software v 4.3 in the MAGPIX system 
(MAGPIX-XPON4.1-CEIVD). Cytokines in both OA samples (OASF-pool and 
OASF#3) yield elevated levels of the majority of cytokines assessed relative to HSF. 
Therefore, the corresponding SF cytokines profiles were utilized along with our results to 
facilitate appropriate interpretation.  
6.2.5 MMT Surgery for femoral lymphatic testing 
Naïve, Sham, and MMT Lewis rats were purchased to determine the effect of 
MMT surgery on downstream lymphatic collector function. Naïve Lewis rats were tested 
two weeks prior and appropriately age-matched to surgical animals. Six Sham and six 
MMT surgeries were performed, and 8-9 weeks post-surgery, femoral lymphatic vessels 
were isolated from the rats. 
6.2.6 Ex vivo lymphatic perfusion system setup 
Figure 24 Ex vivo experimental set up. (a) Picture of the ex vivo lymphatic perfusion 
system including the computer, syringe pump, and microscope. (d) Picture of the 
single vessel chamber with a close-up of the cannulated RFLV. (5x objective; Scale 
bar = 200 μm.) (c) A custom LabView program tracks changes of the vessel diameter 





 An ex vivo lymphatic perfusion system was customized to control the average 
transmural pressure applied to the lymphatic vessel (Figure 24). First, an LV segment 
without branches was cannulated on two resistance-matched glass pipettes of 150–200 
μm tip diameter using the single vessel chamber (Living System Instrumentation, St 
Albans, VT; CH-1) (Figure 26b). After cannulation, the chamber was connected via 
tubing to two glass flasks containing DMEM/F12 and two syringe pumps (Genie 
TouchTM Syringe Pump; Kent Scientific Corporation, Torrington, CT) and immediately 
placed onto the microscope stage. 
The syringe pumps were used to apply the same transmural pressure to the inlet 
and outlet of LV. Transmural pressure was adjusted using a feedback loop with two 
syringe pumps and pressure sensors (1 psi SSC series; Honeywell, Charlotte, NC). 
During the experiment, the diameter tracing was recorded in real-time via a custom 
LabView program, using data from a bright-field camera capturing 30 fps, as in other 
studies146 (Figure 24c). Both diameter data and other sensor data were synchronized post-
experiment using recorded time stamps. From the lymphatic diameter tracings, the 
following lymph pump parameters were calculated 364: 
𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐼𝐼𝑇𝑇𝐼𝐼𝑇𝑇𝐼𝐼(𝐿𝐿𝑇𝑇𝐼𝐼) 𝑇𝑇𝑜𝑜 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 =
𝐷𝐷𝐷𝐷𝐶𝐶𝐶𝐶2+−𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓−𝐷𝐷𝐷𝐷
𝐷𝐷𝐷𝐷𝐶𝐶𝐶𝐶2+−𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓
∙ 100% (1) 








where, 𝐷𝐷𝐷𝐷𝐶𝐶𝐶𝐶2+−𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 is the completely relaxed diameter obtained post-incubation with 
Ca2+ free physiological solution, 𝐷𝐷𝐷𝐷 the diastolic diameter, 𝑆𝑆𝐷𝐷 the systolic diameter, and 
𝐹𝐹𝐹𝐹𝐸𝐸𝐹𝐹 is the contraction frequency. The tone denotes the percentage of vessel constriction 
at the diastolic diameter compared to the fully relaxed diameter obtained with Ca2+ free 
physiological solution. The ejection fraction (𝐸𝐸𝐹𝐹) indicates the fractional amount of the 
end-diastolic volume ejected during a lymphatic contraction. Finally, the fractional pump 
flow (𝐹𝐹𝑃𝑃𝐹𝐹) is an index of active lymph flow that produces the fractional change in 
lymphatic volume per minute. 
For experiments with surgery animals, the vessel was canulated in our perfusion 
system, and a pressure of 3 cm H2O was applied for 30 minutes to allow the vessels to 
re-acclimate to the application of external forces. After 30 minutes, the vessels were 
subjected to 5 minutes at 1.2, 3, 5, 3, and 1.2 cm H2O to precondition the vessels. After 
the preconditioning step, the vessels were subjected to 1.2, 3, and 5 cm of H2O. At the 
end of each experiment, the vessel was equilibrated in Ca2+-free physiological solution 
containing (in mM): 119.0 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.0 NaHCO3, 1.2 
KH2PO4, 0.027 EDTA, and 5.5 glucose for 20 min and subsequently exposed to an 
average transmural pressure of 1, 3, and 5 cm H2O to determine the passive diameter (for 
calculation of tone) at each pressure. 
For the experiments with SF treatment, the “inlet” side of the vessel was removed 
from the glass pipette, and SF was introduced to the corresponding upstream tubing and 




was removed from the glass pipette, and DMEM/F12 was introduced to the 
corresponding upstream tubing and glass cannula. Then, the vessel was re-cannulated, 
and flow with a pressure gradient of 1 cm H2O was generated for 5 seconds (while 
holding the average transmural pressure to 3cm H2O) to confirm the successful 
introduction of OASF, HSF, and DMEM/F12 through the vessel. Next, the vessel 
containing SF or DMEM/F12 was kept at 37 °C for ~1 hr at a transmural pressure of 3 
cm H2O, and the diameter was recorded to monitor changes in contractile behavior. After 
the 1hr-, 2hr- and overnight treatments, average transmural pressures of 1, 3, and 5 cm 
H2O was applied to quantify the contractile response of RFLVs. We should note that we 
are the first to our knowledge to test the contractility of RFLVs ex vivo with SF. During 
our preliminary experiments, we demonstrated that RFLVs do not consistently contract at 
higher average values of transmural pressure. Thus we utilized pressures previously 
applied for rat cervical and thoracic duct lymphatics145,363. At the end of each experiment, 
the vessel was equilibrated in a Ca2+-free physiological solution. 
6.2.7 Hydrogel Preparation 
To prepare PEG hydrogels, solutions were prepared for as previously described19. 
PEG-4MAL macromer (MW 22,000; Laysan Bio) was dissolved in 4-(2-
hydroxyethyl)piperazine-1-ethane sulfonic acid (HEPES) buffer (20 mM HEPES in 
DPBS, pH 7.4) at 2.5x the final density. Adhesive and cross-linking peptides were 
synthesized by AAPPTec. Adhesive peptide RGD (GRGDSPC) was dissolved in HEPES 
at 10.0 mM (5X final ligand density) and mixed with PEG-4MAL at a 2:1 PEG-




minimum of 15 min, the functionalized PEG-4MAL precursor solution was further 
diluted using HEPES buffer at a 3:1 functionalized PEG-4MAL/HEPES ratio. Bis-
cysteine cross-linking peptide GPQ-W (GCRDGPQG↓IWGQDRCG; ↓ denotes 
enzymatic cleavage site) was dissolved in HEPES at 5X the density corresponds to 1:1 
maleimide/cysteine ratio after accounting for maleimide groups reacted with adhesive 
peptide. To assess the mechanical properties, 10 µl gels were synthesized and incubated 
in PBS overnight before testing. Hydrogels were crosslinked in the incubator for 
approximately 15 minutes before media was applied for lymphatic vessel encapsulation.  
To determine whether VEGF-C could drive lymphangiogenesis through the 
formation of sprouts from collecting lymphatic vessels in this platform, samples were 
either treated for five days with control media (10% EBM), VEGF-C media (10 ng/mL), 
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Figure 25 Storage Modulus of PEG-RGD hydrogels assessed via rheology. PEG 
hydrogels were mechanically tested and showed a linear correlation (Y = 75.95*X - 
76.26 (R2=0.994) between polymer density and storage modulus. 6% gels were 




VEGF-C + VEGFR2 + VEGFR3 (10ng/mL, 1ug/mL, 1ug/mL) to attenuate the effects fo 
VEGF-C. To understand the effect of pooled OASF on sprouting, samples were treated 
with either control media (10% FBS supplemented EBM) 10% bovine synovial fluid 
(BSF) or 10% pooled OASF supplemented EBM. 
6.2.8 Hydrogel Characterization 
  The storage moduli of hydrogels of different PEG weight percentages were 
assessed by dynamic oscillatory strain and frequency sweeps performed on an MCR 302 
stress-controlled rheometer (Anton Paar) with a 9-mm diameter, 2° cone, and plate 
geometry(Figure 25). Oscillatory frequency sweeps were used to examine the storage and 
loss moduli (ω = 1–100 rad s-1) at a strain of 2.3%. 
6.2.9 Rodent Lymphatic Isolation and Encapsulation 
Rat femoral lymphatic vessels were collected as previously described for 




lymphatic perfusion studies. To isolate mouse flank vessels, mice were euthanized via 
carbon dioxide. Flank vessels were then isolated by flaying the mice and pulling back the 
skin. For both vessels, after removing the vessels from the surrounding tissue, the vessel 
segment was removed and transported to a petri dish of EBM to remove fat and fascial 
tissue. Hydrogels were form hydrogels aseptically by carefully placing them into a 
solution of the cross-linking peptide in a 12 well plate. A solution of the adhesive 
peptide-functionalized PEG-4MAL macromer was then mixed in and allowed to 
polymerize for 15 min before the addition of the growth medium. Animal procedures were 
performed in compliance with procedures approved by the Georgia Institute of Technology 
Internal Animal Care and Use Committee (IACUC). 
6.2.10 Tissue Culture 
As previously described, rat and mouse vessel segments were cultured in an 
endothelial basal medium (EBM) formulation353. This consisted of EBM (Lonza,) 
supplemented with 10% FBS (Atlanta Biologicals), 1% penicillin-streptomycin (Gibco), 
1% Glutamax (Gibco), 0.1% DBcAMP (Sigma), and 0.1% hydrocortisone acetate 
(Sigma). Vessel segments were cultured for a total of 5 days with no media changes. For 
epsin studies, vessel segments were cultured over the course of 7 days with a media 
change at days 3 and 5. The increased media changes were due to different limitations in 
terms of the availability of reagents. 




Sprouting from rat vessel segments was analyzed via AngioAnalyzer (AA) 
software in ImageJ. Due to size variability, only the new growth from the vessel core was 
analyzed for complexity and normalized to the size of the core. Brightfield images taken 
during confocal images were converted into a maximum intensity projection, and then 
thresholding was used to identify the dark core, and the size of the core in pixels was 
calculated(Figure 26). The WGA image was then used to identify the entire network via 
thresholding, and the ImageJ image calculator tool was then used to subtract the core 
from the image. Finally, all images were converted to grayscale using the lookup table 
(LUT) feature in ImageJ to ensure that the images were in the proper color scheme for 
AA. AA was used with the following settings in batch mode: minimum object size (35), 
minimum branch size (25), artifactual loop size (100), isolated element size threshold 
(50), master segment size threshold (400), iteration number (2), show iteration (2). The 
only unchecked mapping setting was “suppress isolated elements,” and all other options 
were selected. Sprouting from epsin mice was calculated by calculating the core area at 
day 0 and normalizing that to the day 7 area measured by actin staining. 
6.2.12 Immunostaining and Imaging 
RFLV samples were stained to assess morphology and cell type. Tissues were 
fixed for one hour with 4% PFA and washed with PBS 3 times, then stained overnight 
with wheat germ agglutinin (WGA) Alexa Fluor™ 633 conjugate (Invitrogen), which 
stains the cell membrane to assess general morphology. Samples were left to destain for 
at least 4 hours, then placed in a standard solution of DAPI + PBS and imaged via 




Triton-X for 20 minutes and then rinsed three times. After the third rinse, samples were 
blocked for 1 hour in a PBS containing 2% bovine serum albumin. The blocking solution 
was then removed, and samples were incubated with alpha-smooth muscle actin 
(eFluor570) ( (αSMA, Mouse IgG2a, eBioscience) and CD31(AF488) to identify LECs 
(Polyclonal Goat IgG, RND Systems) suspended in a 2% BSA solution (1:200) overnight 
at 4C on a rocker. After a final three rinses, the samples were then imaged using confocal 
microscopy. Nonspecific isotype controls were incubated with samples at the same 
concentration as the primary antibodies to assess the extent of non-specific antibody 
binding. Imaging was conducted on an inverted confocal microscope (Zeiss LSM 
710NLO).   
6.2.13 Statistics 
GraphPad Prism version 7.01 was used for statistical analysis. Student’s t-tests 
were used when appropriate to test significance between two samples. All analyses were 
considered statistically significant if p < 0.05. Error bars on all data points are standard 
error. For the ex vivo lymphatic perfusion experiments, multiple comparisons were 
performed using a one-way or two-way ANOVA followed by a Dunnett multiple-
comparison correction. For all cases, significance was defined as p < 0.05 (#, *, Ø) or p < 
0.01 (##, **), p < 0.001 (###, ***), or p < 0.0001 (####, ****). For the ex vivo 
experiments, a # denotes a comparison with the control DMEM/F12 case, a * with the 






6.3.1 Effect of MMT surgery on lymphatic contractility 
To test the effect of MMT surgery on lymphatic contractility. Lymphatic vessels 
from naïve, Sham, and MMT vessels were isolated 8-9 weeks after surgery or 8-9 weeks 
after the 1-week acclimation period for age match naïve controls. When the tonic activity 
was assessed at each pressure, there were no significant differences between Naïve, 
Sham, and MMT groups(Figure 27). Additionally, when we assessed the phasic 
lymphatic contractility metrics, frequency, fractional pump flow, and ejection fraction, 
we only saw a statistically significant increase in ejection fraction for MMT vessels 
Figure 27 Tonic Contractions following MMT Surgery. Plots of tonic contractions. 
Tone (%) after isolation from Naïve (n=6), Sham (n=5), and MMT(n=5) animals. Each 
plot displays data from experiments at average transmural pressures of 1, 3, and 5 cm 
H2O for RFLVs in APSS. There are no significant differences to report following a two-




compared to Naive at the lowest transmural pressure(Figure 28), perhaps suggesting that 
these vessels are in a hyperactivated contractile state, similar to what was shown in 
collecting lymphatic after remodeling in response to injury in the sheep24. 
 
Figure 28 MMT surgery increases ejection fraction at low pressures. a) Analysis of 
phasic contraction frequency b) fractional pump flow and c) ejection fraction metrics for 
Naïve (n=6), Sham (n=5), and MMT(n=5) groups. Each plot displays data when vessels 
were held at average transmural pressures of 1, 3, and 5 cm H2O. Symbols on top of error 
bars denote comparisons using two-way ANOVA followed by a Dunnett multiple-







6.3.2 OA synovial fluid treatment enhances the tonic contractions in RFLVs 
Figure 29 OASF treatment leads to the abrupt decrease in RFLV contractions. 
Diameter tracing: (a), (c), (e), (g) After 1hr- treatment, and (b), (d), (f), (h) After 
overnight treatment. Individual plots display trace diameters of RFLVs in: (a, b) 
DMEM/F12 (n=7), (c, d) OASF-pool (n=4), (e, f) OASF#3 (n=3), and (g, h) HSF 
(n=3). Average input and output pressures (cm H2O) are displayed on the top trace of 
each plot. They were changed simultaneously from 1 to 3 and 5 cm H2O (labelled). 
The outer diameter (μm) was measured continuously over time and plotted on the 
bottom trace (solid line). The outer diameter in Ca2+-free physiological solution 
(passive diameter; dashed line) was measured at the end of each experiment and plotted 




 A single RFLV was isolated and cannulated on the ex vivo lymphatic perfusion 
system as described above. The RFLVs were treated with OASF#3 and HSF, like the in 
vitro studies, and included treatment with a mixture of pooled OASF from six people 
(OASF-pool).  
First, we sought to investigate the effect of SF treatment on RFLV contractility 
qualitatively. To do so, we tracked the raw traces of RFLV contractions during the 
pressure step protocols after 1 hour or overnight treatment (Figure 29). We found that 
longer incubation times (overnight treatment) with SF led to decreased lymphatic 
diameter oscillations. Notably, OASF treatment (both OASF-pool and OASF#3) 
generated a reduction of diameter oscillations after 1-hr of treatment and a complete 
cessation of oscillations after an overnight treatment; HSF treatment, on the other hand, 
produced a gradual decrease in diameter. For the DMEM/F12 group, RFLV remained 
functional for the duration as indicated by the maintenance of frequent diameter 
oscillations with no significant change in amplitude or frequency at 1 hour or overnight 
timepoints.  
After the pressure ramps and measurements presented above, we subsequently 
tested the corresponding effect of SF treatments on the tonic contractions of the isolated 
vessels. To do so, RFLVs were either left untreated (DMEM/F12) or treated with OASF-
pool, OASF#3, and HSF for 1 hr (Figure 30a). After 1 hour, vessels treated with OASF-
pool exhibited significantly increased tone at all three levels of transmural pressure 
compared to the untreated (DMEM/F12) case; the vessels treated with OASF#3 showed 




(DMEM/F12) case; the vessels treated with HSF showed increased tone at 1 and 3 cm 
H2O compared to the untreated (DMEM/F12) case. Specifically, OASF-pool significantly 
elevated RFLV tonic contractions (by 25.66±5.62 at avP-1, 23.42±8.48 at avP-3, and 
17.02±9.09 at avP-5; p = 0.0005, p = 0.0026, and p = 0.013, respectively). OASF#3 led to 
a significant increase of RFLV tonic contractions only for the lowest transmural pressure 
tested (by 21.25±6.01 at avP-1; p = 0.0201). Finally, HSF increased the tonic contraction 
of RFLVs in comparison to the control DMEM/F12 case (by 20.64±8.89 at avP-1 and 
15.78±7.08 at avP-3; p = 0.0044 and p = 0.0374, respectively). Together, OASF-pool 
treatment was the only treatment that produced statistically significant increased tone for 
all applied transmural pressures.  
Next, we investigated whether this enhanced tonic contraction observed during 
the short SF treatment (1hr- treatment) was maintained after the overnight treatment 
Figure 30 OASF treatment transiently enhances the RFLVs tonic contractions. Plots 
of tonic contractions. Tone (%) after treatment for (a) 1hr and (b) overnight. Each plot 
displays data from experiments at average transmural pressures of 1, 3, and 5 cm H2O for 
RFLVs in DMEM/F12 (n=7; white color), OASF-pool (n=4; black), OASF#3 (n=3; lined 
grey), and HSF (n=3; dark grey). All data represent mean values, and the error bars 
correspond to the standard error of the mean for each condition. Symbols on top of error 
bars denote comparisons using one-way ANOVA followed by a Dunnett multiple-




(Figure 30b). We found that tone was still present (around 5-10%) and was within the 
level of untreated control conditions regardless of treatment, with no significant 
differences observed. Also, we found that at intermediate transmural pressure (avP-3), 
only OASF-pool treatment led to a significant change in tonic contractions. For low 
transmural pressure (avP-1), all SF treatments led to statistically significant tone index 
elevation compared to DMEM/F12.  
6.3.3 OA synovial fluid treatment reduces the phasic contractions of rat femoral 
lymphatic vessels 
Figure 31 OASF treatment gradually reduces and eventually ceases the RFLVs 
phasic contractions. Analysis of phasic contraction metrics after treatment for (a-c) 1hr 
and (d-f) overnight: (a, d) Frequency (/min), (b, e) Ejection Fraction (%), and (c, f) 
Fractional Pump Flow (/min). Each plot displays data when vessels were held at average 
transmural pressures of 1, 3, and 5 cm H2O for RFLVs in DMEM/F12 (n=7; white 
color), OASF-pool (n=4; black), OASF#3 (n=3; lined grey), and HSF (n=3; dark grey). 
All data represent mean values, and the error bars correspond to the standard error of the 
mean for each condition. Symbols on top of error bars denote comparisons using one-way 
ANOVA followed by a Dunnett multiple-comparison correction with, p < 0.05 (#), p < 
0.01 (##), p < 0.001 (###) vs. control DMEM/F12; p < 0.05 (*), p < 0.01 (**) vs. HSF; p 




Here, we analyzed the effect of SF treatment on phasic contractions, namely the 
strong periodic contractions from the diastolic to the systolic diameter of the LV, as can 
be seen in Figure 33. After treatment for 1 hour, we found that the various SF treatments 
yielded different behaviors on the metrics quantifying pump function, namely frequency, 
ejection fraction, and fractional pump flow (Figure 31a-c). Specifically, both OASF-pool 
and OASF#3 significantly decreased the frequency of lymphatic contraction at the 
intermediate transmural pressure (by 10.78±4.27 and 14.02±3.25 at avP-3, respectively; p 
= 0.0088 and p = 0.0012, respectively), while it completely stopped the phasic 
contractions at higher transmural pressure (at avP-5). Contrarily, HSF increased the 
frequency of lymphatic contractions compared to the control DMEM/F12 case for 
intermediate and high average transmural pressures (by 6.08±2.08 at avP-3 and 
6.25±2.43 at avP-5; p = 0.005 and p = 0.0218, respectively). Regarding the ejection 
fraction and fractional pump flow, SF treatment led to similar results. OASF-pool 
decreased the ejection fraction of lymphatic contractions compared to the control 
DMEM/F12 case (by 0.53 ±0.01 at avP-1 and 0.43±0.02 at avP-3; p < 0.0001 and p < 
0.0001, respectively). In addition, OASF#3 decreased the ejection fraction of lymphatic 
contractions compared to the control DMEM/F12 case (by 0.55±0.02 at avP-1 and 
0.46±0.01 at avP-3; p < 0.0001 and p < 0.0001, respectively). Again, OASF-pool and 
OASF#3 stopped phasic contractions at avP-5. Similarly, HSF lowered the ejection 
fraction (by 0.32±0.09 at avP-1, 0.29±0.05 at avP-3, and 0.25±0.05 at avP-5; p = 0.0006, 
p = 0.0007, and p = 0.0016, respectively). Notably, OASF (OASF-pool and OASF#3) 




pressure. Finally, all SF treatments decreased fractional pump flow compared to the 
DMEM/F12 case (namely, OASF-pool: by 5.84 ±0.16 at avP-1 and 7.26±0.27 at avP-3; p 
< 0.0111 and p < 0.0001, respectively; OASF#3: by 5.97±0.27 at avP-1 and 7.94±0.09 at 
avP-3; p = 0.0343 and p < 0.0001, respectively, and HSF: by 3.56 ±0.05 at avP-3 and 
4.28 ±0.05 at avP-5; p = 0.0124 and p = 0.0035, respectively). Notably, OASF treatment 
led to a lower fractional pump flow than the HSF treatment. These data together showed 
that short duration SF treatment (exposure) had no significant effect on the contractile 
frequency at low transmural pressure (avP-1); at intermediate (avP-3) and high (avP-5) 
pressures, OASF (OASF-pool and OASF#3) decreased while HSF increased the observed 
frequency. Finally, all treatments (OASF and HSF) significantly decreased fractional 
pump flow pressure for all applied pressures. Particularly, OASF treatment leads to a 
complete cease of contractions at high transmural pressure (avP-5).  
Finally, we sought to determine whether these responses were maintained after a 
longer incubation (overnight treatment) (Figure 35d-f). OASF-pool and OASF#3 
completely ceased phasic contractions at all applied transmural pressures, i.e., avP-1, 
avP-3, and avP-5. On the other hand, HSF significantly decreased the frequency of 
contractions only at high transmural pressure (by 7.55 ±2.12 at avP-5; p = 0.0195). HSF 
significantly reduced ejection fraction (by 0.27±0.16 at avP-3 and 0.39±0.01 at avP-5; p 
= 0.0114 and p < 0.0001, respectively), and fractional pump flow (by 4.54± at avP-1 and 
3.47±0.08 at avP-5; p = 0.05 and p = 0.0498, respectively). Together, we found that 




contraction, was not nearly as severe as the negative effects of OASF (OASF-pool and 
OASF#3) on lymphatic pump function.  
6.3.4 PEG hydrogel system is tuned to assess pro and anti-lymphangiogenic factors 
 RFLV segments were cultured over 5 days in either control media, VEGF-C 
supplemented media, or VEGF-C with soluble VEGFR2/VEGFR3 media. VEGFC 
significantly increased the # of segments (0.007±0.005 vs. 0.004±0.002, p=0.049) and # 
of nodes (0.018±0.015 vs. 0.0098±0.005, p = 0.038) while the average and total segment 
length was not different compared to control, indicating more branching occurred due to 
Figure 32 VEGF-C increases lymphatic growth metrics. The number of (a) segments, 
the (b) average segment length, (c) # of nodes and (d) total network segment length were 
calculated for lymphatic treated with VEGF-C or VEGF-C with soluble VEGFR3 & 
VEGFR2. VEGF-C treatment significantly increased the overall complexity of the 
network but not the overall network length. Symbols on top of error bars denote 
comparisons using one-way ANOVA followed by a Dunnett multiple-comparison 






VEGF-C. Blocking VEGFR2/3 signaling significantly attenuated the effect of VEGFC on 
sprouting. Figure 33 demonstrates that the sprouts eminating from these vessels are CD31 
positive and therefore endothelial in nature.  
6.3.5 OASF decreases lymphangiogenesis 
CD31
alpha-SMAalpha-SMA CD31
Figure 33 Lymphatic endothelial cells sprout from vessel core VEGF-C treated vessel 
stained for CD31 and alpha smooth muscle actin (alpha-SMA) shows that lymphatic 
endothelial cells sprout from the vessel core and migrate out into the ECM while the 
lymphatic muscle cells as stained by SMA are retained within the vessel core and do not 
significantly migrate and participate in the network. The same applied for vessels not 





Given the ability to assess RFLV sprouting in the presence of pro-and anti-
lymphangiogenic factors given the conditions, we were confident in our ability to tease 
out the effect of OASF in lymphangiogenesis(Figure 34). OASF significantly decreased 
the # of segments  (0.0020 ± 0.0008 vs 0.004±0.002) (p=0.002), nodes (0.005±0.002 vs 
0.009±0.00, p=0.0014), and the average segment length (30.78±6.43 vs37.93±5.02 
pixels, p=0.0009) compared to control samples. Total segment length, however, was not 
significantly different between OASF treated samples and controls. Bovine synovial fluid 
data 
Figure 34 OA synovial fluid treatment reduces lymphatic growth. OASF decreases 
lymphatic growth parameters, specifically the number of segments # of nodes and 
average segment length compared to BSF – supplemented  and 10% FBS EBM control . 
OASF significantly reduced  complexity of the network but not the overall network 
length. Symbols on top of error bars denote comparisons using one-way ANOVA 
followed by Tukey’s multiple-comparison correction vs. Ctrl (10%EBM) p < 0.05 (*), p 
≤ 0.001 (***), or vs BSF p < 0.05 ($), p ≤ 0.01 ($$). 





























































































6.3.6 Epsin deletion decreases sprouting lymphangiogenesis from collecting vessel 
segments 
The in vivo deletion of epsin was assessed by encapsulating mice flank vessels 
from mice with and without in vivo lymphatic-specific knock-out of epsin 2 in PEG 
hydrogels. When epsin DKO mice were compared to control mice (Figure 35), epsin 
staining was significantly reduced, confirming that epsin was successfully deleted. 
To quantify the effect of epsin deletion on lymphatic collecting vessel 
lymphangiogenesis, mouse flank vessels were encapsulated in PEG hydrogels and grown 
in either 1%, 5%, or 20% FBS supplemented EBM growth media. The growth was 
quantified by normalizing the day 0 area in brightfield to the day 7 area via confocal 
imaging(Figure 36) to account for slight differences in initial segment implantation size. 
In 1% serum, the % increase in area was significantly decreased in Epsin DKO compared 
Figure 35 4-hydroxytamoxifen administration results in epsin deletion. Epsin DKO 
mice were generated using a course of 4-hydroxytamoxifen. Compared to mice who were 







to wild type (140.5 ± 35.37 vs. 30.11 ± 18.1, p = 0.0073). However, in 5% and 20% 
serum, there was no significant effect of epsin deletion. These results suggest that in low 
serum conditions, where growth factors are sparse, epsin serves to enhance collecting 
vessel sprouting, perhaps through its involvement in localizing the expression of 
VEGFR3 to tip cells and downregulating its expression elsewhere365. 
6.4 Discussion 
The lymphatic system plays an essential role in maintaining joint homeostasis and 
may contribute to the development and progression of OA6,11,336,337. Previous studies have 
shown that lymphatics play a critical role in the clearance of different molecules from the 
SF of the joint. The SF acts as a lubricant in the joint and serves as a fluid to transport 
nutrients and waste8. During OA disease development and progression, the composition 
of the SF changes as it loses its lubricating properties, and there is a buildup of 
degradation by-products and inflammatory cytokines, which feedback to exacerbate the 
* *
Figure 36 Epsin deletion leads to reduced growth in low serum. Wildtype mice and 
epsin DKO were encapsulated in PEG hydrogels with increasing concentrations of serum 
factors. 1% serum significantly reduced the % increase in area compared to wildtype 
mice. In higher percentages of serum (5% & 20%) epsin deletion did not affect sprouting. 





disease process94,338–340. These changes in SF composition have been thought to be due 
mainly to the production of these factors, but studies on lymphatic function suggest that a 
dysfunctional lymphatic system may also impair the clearance of these factors. 
Furthermore, there is an established correlation between SF clearance and 
progression of arthritis 318. Thus, changes in lymphatic function and permeability in the 
OA disease could potentially lead to increased SF transport into the lymphatics, thus 
suggesting a potential future therapeutic target366–368. Recent studies have even 
established the potential utility of targeting the lymphatic system as a therapeutic 
modality for OA and shown that a regenerative therapy that specifically enhanced 
lymphangiogenesis and lymphatic function could attenuate OA disease development369. 
Despite the importance of the lymphatic system and SF in OA disease, the direct 
relationship between the two is poorly understood. To our knowledge, this work 
constitutes the first ex vivo investigation of how RFLVs respond to SF treatment in the 
case of OA. 
In the first study in this chapter, we isolated RFLVs from surgery animals 9-
weeks post-surgery. We observe acute changes in the contractility of MMTvessels, 
particularly the fractional pump flow at low pressures. These findings suggest that the 
vessel may be in a heightened contractile state, as demonstrated by previous lymphatic 
injury models370. In this sheep study, the lymphatic injury initiated by ligation of one of 
two parallel lymphatic vessels in the hind limb led to structural and functional changes in 
the intact, lymphatic vessel over six weeks. In ex vivo isolated vessel experiments, the 




and vessel compliance, showing that injury can affect parallel or nearby lymphatic vessel 
contractility. One aspect of this sheep study that was not feasible in our study was the in 
vivo imaging of lymphatic contractility through the skin. Post-injury also changed the 
intact lymphatic vessel function in vivo as measured by the NIR function. Future studies 
in the rat could measure in vivo lymphatic function, knee clearance, and ex vivo isolated 
vessel function to see a relationship between the three. Future work could look for 
elevated oxidative stress in lymphatic muscle, and we do not know the long-term 
consequences of this on lymphatics. The kinetics of human disease are much longer than 
in the rat, and the deterioration of lymphatic muscle function may only present with age 
and time. 
OASF treatment of isolated LVs ex vivo transiently enhanced the tonic 
contractions, while it gradually reduced and eventually ceased the RFLVs phasic 
contractions.  Historically, it has been demonstrated that the primary mechanisms used to 
fill the lymphatics are: (1) for initial lymphatics, the extrinsic pump, which responds to 
both steady-state lymph volumes and unsteady initial lymph volumes, and (2) for 
collecting lymphatics, the spontaneous muscle contractions135,141. This intrinsic phasic 
contraction of the lymphatic vessels was abolished entirely after 24 hours of treatment 
with OASF; even though the phasic contractile function was lost, the muscle of the vessel 
still maintained some functional integrity as observed by the presence of vessel tone even 
after the overnight treatment. The loss of phasic contractility suggests that the active 
function of the lymphatics has been impaired while the passive flow or flow-induced 




may still be functional; this would result in impaired and slower clearance from the joint 
which could exacerbate OA progression. HSF also affects the RFLV reducing the 
contractions; however, this effect was not nearly as severe as OASF from either the 
pooled SF or the SF exclusively from patient 3. In addition, the baseline contraction 
frequency of isolated vessels removed from their in vivo microenvironment is generally 
much higher than what has been observed in vivo 371. Thus this reduction in contraction 
with HSF may represent a normal physiologic response.  
Data from the cytokine array provides insight into elevated molecules and warrant 
further investigation (Figure 24). First, IFN-γ inducible protein (IP-10) levels in SF have 
been demonstrated to be inversely associated with the severity of knee OA 372 consistent 
with cytokine levels from the OASF samples in this study (high IP-10 levels only in HSF; 
Figure 23). IFN-γ has also been shown to stimulate the lymphatic endothelium 
facilitating the recirculation of lymphocytes during a local immune response373. IL-8 has 
been demonstrated to play an essential role in lymphatic vessel regeneration and 
endothelial cell growth374,375. Thus its elevated expression in HSF suggests a potential 
role of the lymphatic system as a therapeutic modality. IL-7 has been shown to play a 
crucial role in cartilage degradation during rheumatic diseases and correlated with the 
initiation and progression of OA376–379; it has also been suggested as a potential mediator 
of lymphatic drainage 36. IL-2 has been shown to contribute to the immunopathogenesis 
of rheumatoid arthritis 380. The elevated levels of IL-7 and IL-2 in OASF#3 indicate a 
partial OA phenotype. IL-15 is a pro-inflammatory cytokine that is increased in joint 




cartilage 381, and this is in agreement with the IL-15 elevated expression found in OASF-
pool. Both IL-2 and IL-15 promote the development, homeostasis, and function of 
regulatory T cells in lymphoid tissues 382,383. Their high expression in OASF#3 and OAS 
F-pool, respectively, suggests a potentially strong implication of the lymphatic system. 
The gradual diminishment of both tonic and phasic contractions was observed with the 
increase of SF treatment time. Furthermore, the average size of the above cytokines (~ 20 
kDa) suggests clearance through draining lymph nodes after entering the interstitial fluid 
space 220,249. This provides strong evidence on the importance of establishing 
representative ex vivo models for the investigation of OA.  
The ex vivo systems are models by which we can investigate the effects of SF on 
collecting vessel lymphangiogenesis and RFLV function, yet as model systems, they 
have their limitations. To approximate the amount of SF that might end up in the lymph, 
we chose to dilute the SF to 10% of the volume of the media that was perfused through 
the lumen of the vessel contained SF. This was an approximation as it is unclear what the 
exact dilution of SF contents is within the pre-nodal lymph immediately draining the 
vessel. Furthermore, the relative concentrations of proteins and molecules between the 
two compartments are likely a function of the size of the individual molecule, as has been 
shown in other tissue beds8,384. In addition, as mentioned earlier, the frequency of 
lymphatic contractions in these idealized isolated vessel preparations is often higher than 
what is observed in vivo, suggesting that there are factors from the in vivo context that are 
not recapitulated in the isolated vessel preparation. Another limitation is the limited 




the limited availability of SF from OA patients, the experimental outcome may be highly 
patient-dependent. Thus, the interpretation/ extrapolation of these observations should be 
conducted with caution. Another similar restriction is the limited amount of SF, which 
challenged the execution of both the in vitro and ex vivo experiments. Another limitation 
is the use of human-derived SF to treat rat vessel segments and rat-derived collecting 
vessels(ex vivo studies).  
In this CHAPTER we also used the PEG hydrogel platform to determine the 
effect of OASF on lymphangiogenesis. In order to do so, we first determined the 
phenotype for femoral lymphatic vessels in response to VEGF-C treatment. VEGF-C 
treatment did not increase the network area. However, it increased the sprouting 
complexity as represented by more segments and decreased average branch length, which 
Bruyere et al. showed by quantifying the number of intersections at defined distances 
from the core.  Additionally, as previously demonstrated in other studies, we wanted to 
demonstrate whether this response to VEGF-C could be attenuated by blocking VEGF-C 
signaling with the addition of exogenous soluble VEGFR2 and VEGFR3. 
Given that n # of continuous nodes (n-1) would make up n-1# of segments or 
branches, the number of nodes corresponded closely with the number of branches. After 
demonstrating that the collecting vessel networks increase their sprouting complexity, but 
not overall sprout length, in response to VEGF-C, we then used pooled OASF to 
determine if it had a pro or anti-lymphangiogenic effect. One of the limitations of this 




synovial fluid to control non-OA SF, which could be purchased in quantities comparable 
to that of OASF.  
OASF treatment of lymphatics in the hydrogel significantly reduced 
lymphangiogenesis as measured by the number of segments. These samples were 
collected from patients with effusions. Therefore, this decreased lymphangiogenesis 
could indicate how synovial effusion presents in vivo as Walsh et al. showed that joint 
effusion was well correlated with reduced lymphatic vessel density6. While the exact 
molecular mechanisms responsible for this reduction in lymphatic sprouting remain 
unknown, future work should encompass which genes are dysregulated after treatment 
with OASF and which cytokines present in the synovial fluid have the most significant 
impact. Some of the pro-lymphangiogenic cytokines found in the pooled synovial fluid 
include IL-1a, VEGF, Flt-3L, while other cytokines like IL-1RA and IL-10 are directly 
and indirectly anti-angiogenic in vivo. One of the limitations of our study is that many of 
the factors present in synovial fluid regulate lymphangiogenesis through primary 
mechanisms with t-cells or macrophages; however, these support cells are not present in 
great quantity in our system370,385. A secondary limitation of our study was that bovine 
synovial fluid was used as our non-OA synovial fluid control. However, this is a first 
dive into the effect of OA on lymphangiogenesis ex vivo, and bovine synovial fluid has 
been used as a control for study synovial fluid viscosity. Additionally, in mammals, many 
small proteins are well conserved. 
Given the demonstrated importance of epsins in regulating VEGFR3 expression 




of epsin deletion on mature collecting vessels lymphangiogenesis. Epsin deletion in a 
variety of contexts has been shown to increase lymphangiogenesis33,157,169. Therefore, we 
hypothesized that epsin deletion in our context would also increase lymphangiogenesis 
from collecting vessels. However, we saw that in high serum, where growth factors were 
abundant, epsin deletion did not affect lymphangiogenesis. However, in reduced serum 
conditions, epsin DKO reduced growth from the vessel core. In vivo, the patterning of 
VEGFR3 receptors in lymphatics is well regulated157,386,387. VEGFR3 is expressed in 
abundance at the capillary level compared to the collecting vessels that only express 
VEGFR3 at the valves365. Thus, collecting vessels may upregulate VEGFR3 expression 
to induce lymphangiogenesis appropriately, and epsin dysregulation may alter that 
process. Future work must be conducted to tease out the differences between capillary 
lymphangiogenesis and collecting vessel lymphangiogenesis. This differential response 
with epsin deletion may be one of the first explorations into how these two tissues may 
differ in that way. 
6.5 Conclusions 
This work utilized a surgical model of OA and a simulated OA environment to 
investigate the potential effect of SF draining into lymph fluid on lymphatic function and 
contractility. MMT surgery did not significantly affect lymphatic contractility compared 
to sham vessels; however, it significantly affected contractility on low pressure. Finally, 
it is worth noting that the vessels were removed from an in vivo environment, 
demonstrating that these parameters should be tested in vivo as future technologies allow 




The striking effect of OASF (OASF-pool and OASF#3), which significantly 
attenuated and eventually completely impaired the tonic and phasic lymphatic 
contractions, demonstrates a critical relationship between diseased SF and the lymphatic 
system, which could play an essential role in the progression of OA114,319,337,388,389. 
Additionally, isolating specific factors that have the most potent effect on contractility 
and lymphangiogenesis could provide a new therapeutic target and would be highly 
beneficial when combined with other regenerative and restorative therapies in treating 
OA patients. 
Using the PEG hydrogel system, we were able to establish two significant 
findings. Firstly, pooled OASF had a negative effect on lymphangiogenesis ex vivo. We 
used the synovial fluid control as bovine synovial fluid, which may not adequately 
simulate human synovial fluid to synovial fluid. Future synovial fluid studies should be 
done with human samples and genetic analysis tools that can assess which genes are 
dysregulated with synovial fluid treatment. Our second significant finding with the PEG 
hydrogel was that collecting vessel lymphangiogenesis was not significantly increased 
via the deletion of epsin as demonstrated in initial lymphatics and with dermal LECs33. 
Additionally, in reduced serum factors, lymphangiogenesis sensitivity was decreased, 
showing that lymphangiogenesis at the different hierarchal levels of lymphatic structure 






CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
The work reported in this thesis supported many principal contributions. 
1. We established that ET-1 could significantly decrease venous and lymphatic 
drainage from the joint. 
2. Developed multichromatic NIR imaging to assess venous and lymphatic drainage 
and saw that exercise transiently increases lymphatic clearance in vivo.  
3. We determined the dynamic effect of MMT surgery on microvascular clearance, 
showing that venous clearance increased at early time points and that lymphatic 
clearance is decreased at later stages from the joint space. 
4. Using treadmill running with rats, we established an initial mechanism by which 
exercise may improve joint function and health by increasing clearance at later 
time points. 
5. We established a link between reduced collecting lymphatic vessel contractility 
and OA synovial fluid. 
6. Using a PEG hydrogel sprouting platform with collecting lymphatic vessels, we 
showed that: 
a. OA synovial fluid treatment significantly reduces lymphangiogenesis  





 Intra-articular clearance has been investigated in the context of rheumatic and 
arthritic diseases for a half-century. Particularly iodinated proteins have been used to 
assess lymphatic function and free radioiodine as a metric for venous 
clearance111,219,253,390. These seminal works have laid the foundation of this thesis to help 
establish normal and disease venous and lymphatic clearance. In addition, previously 
reduced lymphatic function either through downstream clearance or lymphatic vessel 
uptake in the joint has been considered a potential mechanism for joint dysfunction, but 
the in vivo functional effects remain understudied. The work presented in this thesis 
represents two technological and scientific advances in the way we can study OA. Firstly, 
multichannel NIR imaging can be used to assess tracer clearance from the joint space 
with great sensitivity, and secondly, ex vivo platforms to test lymphatic vessel 
contractility and lymphangiogenesis in the context of externally applied biochemical 
signals. 
 Through NIR imaging, we learned that the synovial fluid is very effective at 
retaining intra-articularly delivered biomolecules. This retention is likely one of the 
intentional biological functions to slow down the flow of materials from the joint space 
and retain water and nutrients balance. We learned that our post-traumatic OA model had 
a dynamic change in venous and lymphatic clearance with a contralateral control. In the 
context of exercise, we showed that exercise only had a modest effect on lymphatic 





In this thesis, we determined that synovial lymphatics are sensitive to the OA 
environment. The use of ex vivo lymphatic perfusion systems has enabled us to answer 
complex questions in the field of lymphatic because we have more precise controls over 
individual factors such as pressure, flow, and biochemical environment. Additionally, we 
showed that synovial lymphatic collecting vessel sprouting is significantly reduced in the 
presence of OASF, an observation that corresponds with the observed decreases in 
human lymphatic vessel density. In CHAPTER 3, we showed that ET-1 could completely 
abrogate flow from the joint for hours only for flow to resume eventually. Similarly, in 
these ex vivo lymphatic platforms, we determined that lymphatics lost their phasic 
contractile activity with synovial fluid treatment. These in vivo and ex vivo studies are 
some additional pieces that could explain how joint clearance is altered in OA. 
7.2 Future Directions 
The findings in this thesis have led to several questions that should be addressed 
going forward. The potential research initiatives that could be explored in the future 
encompass the following set fundamental questions: 
(1) Does the intensity and duration of exercise affect the rate of clearance of materials 
from the joint space? 
(2) How does clearance change in spontaneously occurring or non-surgical models of 
OA? 
(3) How do HA sieving and HA size change with OA progression? 




(5) Can this lymphatic sprouting platform be used as a screening platform for lymphatic 
targeting treatments in OA? 
(6) How do lymphatic collecting vessels respond to flow after treatment with OASF? 
The multichannel NIR imaging approach has shown to be sensitive to detecting 
changes in vascular clearance in vivo. Given these resources, multiple approaches can be 
implored to elucidate further the effect of exercise, spontaneous OA, and PTOA on joint 
clearance. The use of larger HA tracers in these contexts could provide better information 
about HA diffusivity, synovial permeability, and HA catabolism, as previously shown221. 
While it is difficult to uncouple these two parameters in vivo, using modeling techniques, 
histological analysis, and NIR imaging could help elucidate fluid and macromolecule 
transport changes in the joint. Next-generation NIR imaging, NIR-II, could provide a 
deeper (imaging depth-related pun) perspective on microvascular function in vivo, given 
its ability to visualize deeper structures in vivo391. Currently, the downstream femoral 
lymphatic function in rats or humans has not been assessed in OA in vivo.  That type of 
experiment would require surgically creating an imaging window or doing a terminal 
experiment where the skin is exposed. 
Currently, NIR imaging is limited by the larger machinery necessary to acquired 
data; however, as wearable sensors become a more feasible technology in the context of 
NIR imaging, then this will allow us to sample data at a much higher frequency and show 
the instantaneous effects of interventions like exercise, PTOA, and ET-1 on 
microvascular clearance. One of our system's limitations was our inability to decouple 




the mechanisms by which we could improve our ability to differentiate the changes in 
OA would be to use HA as the material we are tracking. By guaranteeing that the 
material of interest would also participate in the synovial fluid matrix, we would be able 
to long-term assess the effect of PTOA on HA catabolism and HA clearance from the 
joint space. Lastly, to connect the dots between changes in clearance, synovial fluid 
integrity and to consider biochemical approaches to reducing OA's effect on joint 
function, there is a significant need for synovial fluid analysis and synovial membrane 
quantification. 
One of the limitations of the MMT model used in this thesis is that it requires a 
major surgical insult which may affect our interpretation of the clearance data. Using a 
less invasive model of OA to investigate clearance could provide more usefulness about 
the progressive nature of microvascular changes in OA392. Another technical 
advancement that would significantly improve our understanding of how intra-articular 
pressure changes in the context of OA would be a wearable IAP pressure monitor. 
Additionally, using contrast agents to assess joint volume could help understand how IA 
injections and disease affect synovial fluid volume. 
Using lymphatics in two ex vivo contexts allowed us to elucidate mechanisms that 
are difficult to observe in vivo in real-time. While the limitations of ex vivo systems are 
that the tissues are generally exposed to fewer factors (i.e., cells, mechanical forces) than 
they would be in vivo, in many ways, the innovative use of clinical patient samples 
allowed us to attempt to recapitulate the in vivo OA environment. In terms of lymphatic 




However, using our lymphatic pressurization system setups, we only modulated 
transmural pressure. In the future, we could determine the effect of flow on lymphatic 
contractility in response to the OASF treatment. Additionally, understanding if the 
proteome of the synovial fluid and the downstream lymph are similar could allow us to 
understand the proper way to model lymph from the knee joint. 
Lymphangiogenesis has been classically understudied in vitro. Many advances in 
knowledge about lymphangiogenesis have been made studying embryonic development. 
However, mature collecting vessel lymphangiogenesis remains significantly understudied 
today, and this PEG hydrogel platform has created a tunable medium by which we can 
explore a variety of intrinsic and extrinsic factors that regulate lymphatic growth.  In 
addition to using lymphatic tissues, we could only combine different cell types with 
lymphatic in vitro to determine what effect support cells like synoviocytes and 
macrophages have on lymphatic growth. Given the rat synovium structure, it could serve 
as a tissue to extract and culture in hydrogels. Co-culture could help explore what role 
synoviocytes, lymphatic, blood vessels, and resident cells within the synovium play on 
lymphatics. Lymphatic vessels cultured with synovial tissue from OA animals (horses, 
pigs, rats) and this co-culture system could explain how cellular communication between 
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